[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$frONQMaKEAhQI4HX32zEs7Q4zVpbVb24lSBeV5e5rAtQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":50,"rows":57},"Idorsia Pharmaceuticals Ltd.",[4],99,false,3,14,17876,4,1,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Healthy Subjects",30,{"name":18,"count":19},"Healthy",26,{"name":21,"count":22},"Insomnia Disorder",8,{"name":24,"count":25},"Aneurysmal Subarachnoid Hemorrhage",5,{"name":27,"count":8},"Fabry Disease",{"name":29,"count":30},"Acute Heart Failure",2,{"name":32,"count":30},"Acute Decompensation of Chronic Heart Failure",{"name":34,"count":30},"New Onset of Heart Failure",[36,41,46],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06393504","Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)","2028-04","Daridorexant",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT03737214","A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease","2029-08","Lucerastat",{"nctId":47,"briefTitle":48,"date":49,"intervention":40},"NCT06498128","Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®","2033-03",[51,52,53,54,55,56],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[58,139,251,269,287,350,411,441,496,561,587,624,659,681,699,717,860,901,929,965,983,1001,1019,1037,1062,1086,1112,1130,1148,1166,1184,1207,1225,1249,1320,1366,1392,1418,1459,1501,1527,1560,1593,1617,1635,1653,1671,1689,1707,1725,1743,1766,1796,1814,1832,1850,1868,1886,1904,1922,1940,1958,1981,1999,2017,2035,2063,2081,2099,2117,2135,2164,2182,2200,2218,2236,2254,2272,2290,2308,2331,2357,2375,2393,2411,2429,2447,2465,2483,2501,2519,2537,2562,2580,2598,2616,2634,2652,2670,2688,2711,2735,2753,2778,2796,2814,2846,2864,2882,2900,2918,2936,2954,2972,2990,3008,3026,3044,3067,3085,3103,3129,3147,3165,3183,3201,3224],{"intervention":45,"totalTrials":59,"cells":60},7,{"EARLY_PHASE1":61,"PHASE1":64,"PHASE2":113,"PHASE3":115,"PHASE4":135,"NA":137},{"trials":62,"activeCount":63},[],0,{"trials":65,"activeCount":63},[66,77,86,95,104],{"nctId":67,"briefTitle":68,"status":69,"phases":70,"primaryCompletion":71,"completion":71,"start":72,"enrollment":73,"conditions":74,"interventions":75},"NCT03832452","A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function","COMPLETED",[52],"2019-04-22","2019-02-14",44,[18],[45,76,45,45],"Moxifloxacin",{"nctId":78,"briefTitle":79,"status":69,"phases":80,"primaryCompletion":81,"completion":81,"start":82,"enrollment":83,"conditions":84,"interventions":85},"NCT02944474","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lucerastat (CDP923) After Multiple Dosing in Healthy Subjects",[52],"2004-05","2003-12",37,[15],[45],{"nctId":87,"briefTitle":88,"status":69,"phases":89,"primaryCompletion":90,"completion":90,"start":91,"enrollment":9,"conditions":92,"interventions":93},"NCT02930655","A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease",[52],"2016-02-01","2015-02-01",[27],[45,94],"Enzyme replacement therapy",{"nctId":96,"briefTitle":97,"status":69,"phases":98,"primaryCompletion":99,"completion":99,"start":100,"enrollment":101,"conditions":102,"interventions":103},"NCT02944487","A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy Subjects",[52],"2002-12","2002-10",39,[15],[45],{"nctId":105,"briefTitle":106,"status":69,"phases":107,"primaryCompletion":108,"completion":108,"start":109,"enrollment":9,"conditions":110,"interventions":111},"NCT03380455","Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects",[52],"2018-01-29","2018-01-09",[15],[45,112],"Cimetidine",{"trials":114,"activeCount":63},[],{"trials":116,"activeCount":12,"soonestReadout":44},[117,125],{"nctId":42,"briefTitle":43,"status":118,"phases":119,"primaryCompletion":44,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":124},"ACTIVE_NOT_RECRUITING",[54],"2029-11","2018-12-18",107,[27],[45],{"nctId":126,"briefTitle":127,"status":69,"phases":128,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":134},"NCT03425539","Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease",[54],"2021-08-17","2021-09-02","2018-06-21",118,[27],[45],{"trials":136,"activeCount":63},[],{"trials":138,"activeCount":63},[],{"intervention":40,"totalTrials":140,"cells":141},10,{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":206,"PHASE3":208,"PHASE4":220,"NA":233},{"trials":143,"activeCount":63},[],{"trials":145,"activeCount":63},[146,157,167,179,189,198],{"nctId":147,"briefTitle":148,"status":69,"phases":149,"primaryCompletion":150,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":154},"NCT05480475","A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Dabigatran and Rosuvastatin in Healthy Male Subjects",[52],"2022-09-17","2022-09-03",24,[18],[155,156,40],"Dabigatran etexilate","Rosuvastatin",{"nctId":158,"briefTitle":159,"status":69,"phases":160,"primaryCompletion":161,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":166},"NCT05458193","A Study to Investigate the Effects of Daridorexant on Nighttime Breathing in Patients With Shallow or Paused Breath During Sleep",[52],"2023-02-28","2022-08-17",20,[165],"Obstructive Sleep Apnea of Adult",[40],{"nctId":168,"briefTitle":169,"status":69,"phases":170,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":176},"NCT05480488","A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Midazolam and Warfarin in Healthy Male Subjects",[52],"2022-09-23","2022-10-06","2022-08-23",18,[18],[177,178,40],"Midazolam","Warfarin",{"nctId":180,"briefTitle":181,"status":69,"phases":182,"primaryCompletion":183,"completion":183,"start":184,"enrollment":152,"conditions":185,"interventions":186},"NCT04390334","A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.",[52],"2020-06-26","2020-05-13",[18],[40,187,188],"Famotidine","Efavirenz",{"nctId":190,"briefTitle":191,"status":69,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":197},"NCT04250506","A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects",[52],"2020-07-22","2020-02-28",36,[18],[40,76],{"nctId":199,"briefTitle":200,"status":69,"phases":201,"primaryCompletion":202,"completion":202,"start":203,"enrollment":140,"conditions":204,"interventions":205},"NCT05632393","A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women",[52],"2023-04-30","2023-01-16",[18],[40],{"trials":207,"activeCount":63},[],{"trials":209,"activeCount":63},[210],{"nctId":211,"briefTitle":212,"status":69,"phases":213,"primaryCompletion":214,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":219},"NCT03575104","Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep",[54],"2020-04-09","2020-05-14","2018-05-29",924,[21],[40],{"trials":221,"activeCount":63},[222],{"nctId":223,"briefTitle":224,"status":69,"phases":225,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":232},"NCT05597020","A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia",[55],"2024-04-12","2024-04-18","2023-02-16",60,[21,231],"Nocturia",[40],{"trials":234,"activeCount":30,"soonestReadout":39},[235,244],{"nctId":47,"briefTitle":48,"status":236,"phases":237,"primaryCompletion":49,"completion":49,"start":238,"enrollment":239,"conditions":240,"interventions":242},"RECRUITING",[],"2024-11-21",785,[241],"Insomnia",[40,243],"Non-orexin receptor antagonist medications for insomnia",{"nctId":37,"briefTitle":38,"status":118,"phases":245,"primaryCompletion":39,"completion":39,"start":246,"enrollment":247,"conditions":248,"interventions":249},[],"2023-11-30",2095,[21],[40,250],"Non-orexin receptor antagonist insomnia medication",{"intervention":243,"totalTrials":12,"cells":252},{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":263},{"trials":254,"activeCount":63},[],{"trials":256,"activeCount":63},[],{"trials":258,"activeCount":63},[],{"trials":260,"activeCount":63},[],{"trials":262,"activeCount":63},[],{"trials":264,"activeCount":12,"soonestReadout":49},[265],{"nctId":47,"briefTitle":48,"status":236,"phases":266,"primaryCompletion":49,"completion":49,"start":238,"enrollment":239,"conditions":267,"interventions":268},[],[241],[40,243],{"intervention":250,"totalTrials":12,"cells":270},{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":277,"PHASE4":279,"NA":281},{"trials":272,"activeCount":63},[],{"trials":274,"activeCount":63},[],{"trials":276,"activeCount":63},[],{"trials":278,"activeCount":63},[],{"trials":280,"activeCount":63},[],{"trials":282,"activeCount":12,"soonestReadout":39},[283],{"nctId":37,"briefTitle":38,"status":118,"phases":284,"primaryCompletion":39,"completion":39,"start":246,"enrollment":247,"conditions":285,"interventions":286},[],[21],[40,250],{"intervention":288,"totalTrials":25,"cells":289},"Daridorexant 25 mg",{"EARLY_PHASE1":290,"PHASE1":292,"PHASE2":313,"PHASE3":325,"PHASE4":346,"NA":348},{"trials":291,"activeCount":63},[],{"trials":293,"activeCount":63},[294,303],{"nctId":295,"briefTitle":296,"status":69,"phases":297,"primaryCompletion":298,"completion":298,"start":299,"enrollment":195,"conditions":300,"interventions":301},"NCT05702177","A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented",[52],"2023-04-25","2023-01-05",[18],[288,302],"Daridorexant 50 mg",{"nctId":304,"briefTitle":305,"status":69,"phases":306,"primaryCompletion":307,"completion":307,"start":308,"enrollment":309,"conditions":310,"interventions":311},"NCT05877222","A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants",[52],"2023-08-04","2023-06-23",38,[18],[312,288],"Daridorexant 10 mg",{"trials":314,"activeCount":63},[315],{"nctId":316,"briefTitle":317,"status":69,"phases":318,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":323,"interventions":324},"NCT05423717","Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to \u003C 18 Years With Insomnia Disorder",[53],"2026-01-12","2026-02-05","2022-09-06",166,[241],[312,288,302],{"trials":326,"activeCount":63},[327,336],{"nctId":328,"briefTitle":329,"status":69,"phases":330,"primaryCompletion":331,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":335},"NCT03679884","Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep",[54],"2021-02-22","2018-10-09",804,[21],[312,288,302],{"nctId":337,"briefTitle":338,"status":69,"phases":339,"primaryCompletion":340,"completion":341,"start":342,"enrollment":343,"conditions":344,"interventions":345},"NCT03545191","Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder",[54],"2020-01-25","2020-02-25","2018-06-04",930,[21],[288,302],{"trials":347,"activeCount":63},[],{"trials":349,"activeCount":63},[],{"intervention":351,"totalTrials":25,"cells":352},"Clazosentan",{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":374,"PHASE3":385,"PHASE4":407,"NA":409},{"trials":354,"activeCount":63},[],{"trials":356,"activeCount":63},[357,366],{"nctId":358,"briefTitle":359,"status":69,"phases":360,"primaryCompletion":361,"completion":361,"start":362,"enrollment":9,"conditions":363,"interventions":364},"NCT03596294","A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan",[52],"2018-08-03","2018-07-19",[15],[351,365],"Rifampicin",{"nctId":367,"briefTitle":368,"status":69,"phases":369,"primaryCompletion":370,"completion":370,"start":371,"enrollment":195,"conditions":372,"interventions":373},"NCT03657446","A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function",[52],"2018-10-26","2018-09-18",[15],[351,76],{"trials":375,"activeCount":63},[376],{"nctId":377,"briefTitle":378,"status":69,"phases":379,"primaryCompletion":380,"completion":380,"start":381,"enrollment":382,"conditions":383,"interventions":384},"NCT02560532","Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage",[53],"2017-05-02","2016-03-01",25,[24],[351],{"trials":386,"activeCount":63},[387,397],{"nctId":388,"briefTitle":389,"status":69,"phases":390,"primaryCompletion":391,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":396},"NCT03585270","Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain",[54],"2022-06-13","2022-11-18","2019-02-03",409,[24],[351],{"nctId":398,"briefTitle":399,"status":69,"phases":400,"primaryCompletion":401,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":406},"NCT00558311","Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping",[54],"2010-06-15","2010-07-13","2007-12-14",1157,[24],[351],{"trials":408,"activeCount":63},[],{"trials":410,"activeCount":63},[],{"intervention":302,"totalTrials":11,"cells":412},{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":421,"PHASE3":427,"PHASE4":437,"NA":439},{"trials":414,"activeCount":63},[],{"trials":416,"activeCount":63},[417],{"nctId":295,"briefTitle":296,"status":69,"phases":418,"primaryCompletion":298,"completion":298,"start":299,"enrollment":195,"conditions":419,"interventions":420},[52],[18],[288,302],{"trials":422,"activeCount":63},[423],{"nctId":316,"briefTitle":317,"status":69,"phases":424,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":425,"interventions":426},[53],[241],[312,288,302],{"trials":428,"activeCount":63},[429,433],{"nctId":328,"briefTitle":329,"status":69,"phases":430,"primaryCompletion":331,"completion":331,"start":332,"enrollment":333,"conditions":431,"interventions":432},[54],[21],[312,288,302],{"nctId":337,"briefTitle":338,"status":69,"phases":434,"primaryCompletion":340,"completion":341,"start":342,"enrollment":343,"conditions":435,"interventions":436},[54],[21],[288,302],{"trials":438,"activeCount":63},[],{"trials":440,"activeCount":63},[],{"intervention":442,"totalTrials":11,"cells":443},"tezosentan",{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":462,"PHASE4":492,"NA":494},{"trials":445,"activeCount":63},[],{"trials":447,"activeCount":63},[],{"trials":449,"activeCount":63},[450],{"nctId":451,"briefTitle":452,"status":453,"phases":454,"primaryCompletion":455,"completion":456,"start":457,"enrollment":8,"conditions":458,"interventions":460},"NCT01077297","Tezosentan in Pulmonary Arterial Hypertension","TERMINATED",[53],"2010-11","2011-09","2010-08",[459],"Pulmonary Arterial Hypertension",[461],"Tezosentan",{"trials":463,"activeCount":63},[464,473,485],{"nctId":465,"briefTitle":466,"status":69,"phases":467,"primaryCompletion":468,"completion":468,"start":469,"enrollment":470,"conditions":471,"interventions":472},"NCT00525707","Tezosentan in Acute Heart Failure",[54],"2005-01","2003-04",735,[29,32,34],[442],{"nctId":474,"briefTitle":475,"status":453,"phases":476,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":484},"NCT00458276","Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery",[54],"2008-02","2008-03","2007-04",274,[482,483],"Heart Diseases","Hypertension, Pulmonary",[442],{"nctId":486,"briefTitle":487,"status":69,"phases":488,"primaryCompletion":468,"completion":468,"start":469,"enrollment":489,"conditions":490,"interventions":491},"NCT00524433","Tezosentan in the Treatment of Acute Heart Failure",[54],713,[29,32,34],[442],{"trials":493,"activeCount":63},[],{"trials":495,"activeCount":63},[],{"intervention":497,"totalTrials":11,"cells":498},"Aprocitentan 25 mg",{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":514,"PHASE3":531,"PHASE4":557,"NA":559},{"trials":500,"activeCount":63},[],{"trials":502,"activeCount":63},[503],{"nctId":504,"briefTitle":505,"status":69,"phases":506,"primaryCompletion":507,"completion":508,"start":509,"enrollment":510,"conditions":511,"interventions":512},"NCT04281342","To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women",[52],"2021-08-03","2021-09-03","2020-01-14",48,[15],[497,513],"Aprocitentan 100 mg",{"trials":515,"activeCount":63},[516],{"nctId":517,"briefTitle":518,"status":69,"phases":519,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":524,"interventions":526},"NCT02603809","Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension",[53],"2017-02-28","2017-04-07","2015-12-14",1659,[525],"Essential Hypertension",[527,528,497,529,530],"Aprocitentan 5 mg","Aprocitentan 10 mg","Aprocitentan 50 mg","Lisinopril 20 mg",{"trials":532,"activeCount":63},[533,545],{"nctId":534,"briefTitle":535,"status":69,"phases":536,"primaryCompletion":537,"completion":538,"start":539,"enrollment":540,"conditions":541,"interventions":543},"NCT03541174","A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety",[54],"2021-05-14","2022-04-25","2018-06-18",730,[542],"Resistant Hypertension",[544,497],"Aprocitentan 12.5 mg",{"nctId":546,"briefTitle":547,"status":548,"phases":549,"primaryCompletion":550,"completion":551,"start":552,"enrollment":63,"conditions":553,"interventions":556},"NCT04162366","A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.","WITHDRAWN",[54],"2021-06-30","2021-07-15","2020-01",[554,555],"Hypertension","Renal Insufficiency, Chronic",[497],{"trials":558,"activeCount":63},[],{"trials":560,"activeCount":63},[],{"intervention":312,"totalTrials":8,"cells":562},{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":571,"PHASE3":577,"PHASE4":583,"NA":585},{"trials":564,"activeCount":63},[],{"trials":566,"activeCount":63},[567],{"nctId":304,"briefTitle":305,"status":69,"phases":568,"primaryCompletion":307,"completion":307,"start":308,"enrollment":309,"conditions":569,"interventions":570},[52],[18],[312,288],{"trials":572,"activeCount":63},[573],{"nctId":316,"briefTitle":317,"status":69,"phases":574,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":575,"interventions":576},[53],[241],[312,288,302],{"trials":578,"activeCount":63},[579],{"nctId":328,"briefTitle":329,"status":69,"phases":580,"primaryCompletion":331,"completion":331,"start":332,"enrollment":333,"conditions":581,"interventions":582},[54],[21],[312,288,302],{"trials":584,"activeCount":63},[],{"trials":586,"activeCount":63},[],{"intervention":588,"totalTrials":30,"cells":589},"Clazosentan 15 mg\u002Fh",{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":594,"PHASE3":607,"PHASE4":620,"NA":622},{"trials":591,"activeCount":63},[],{"trials":593,"activeCount":63},[],{"trials":595,"activeCount":63},[596],{"nctId":597,"briefTitle":598,"status":69,"phases":599,"primaryCompletion":600,"completion":600,"start":601,"enrollment":602,"conditions":603,"interventions":604},"NCT00111085","Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)",[53],"2006-03-30","2005-01-10",413,[24],[605,606,588],"Clazosentan 1 mg\u002Fh","Clazosentan 5 mg\u002Fh",{"trials":608,"activeCount":63},[609],{"nctId":610,"briefTitle":611,"status":453,"phases":612,"primaryCompletion":613,"completion":614,"start":615,"enrollment":616,"conditions":617,"interventions":618},"NCT00940095","Clazosentan in Aneurysmal Subarachnoid Hemorrhage",[54],"2010-10-01","2011-01-01","2009-07-01",577,[24],[619,588],"Clazosentan 5 m\u002Fh",{"trials":621,"activeCount":63},[],{"trials":623,"activeCount":63},[],{"intervention":625,"totalTrials":30,"cells":626},"ACT-129968",{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":631,"PHASE3":643,"PHASE4":655,"NA":657},{"trials":628,"activeCount":63},[],{"trials":630,"activeCount":63},[],{"trials":632,"activeCount":63},[633],{"nctId":634,"briefTitle":635,"status":69,"phases":636,"primaryCompletion":637,"completion":637,"start":455,"enrollment":638,"conditions":639,"interventions":641},"NCT01241214","Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis",[53],"2011-02",579,[640],"Seasonal Allergic Rhinitis",[625,625,642],"Cetirizine",{"trials":644,"activeCount":63},[645],{"nctId":646,"briefTitle":647,"status":69,"phases":648,"primaryCompletion":649,"completion":650,"start":651,"enrollment":652,"conditions":653,"interventions":654},"NCT01484119","Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis",[54],"2012-02","2012-03","2011-12",630,[640],[625,642],{"trials":656,"activeCount":63},[],{"trials":658,"activeCount":63},[],{"intervention":642,"totalTrials":30,"cells":660},{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":671,"PHASE4":677,"NA":679},{"trials":662,"activeCount":63},[],{"trials":664,"activeCount":63},[],{"trials":666,"activeCount":63},[667],{"nctId":634,"briefTitle":635,"status":69,"phases":668,"primaryCompletion":637,"completion":637,"start":455,"enrollment":638,"conditions":669,"interventions":670},[53],[640],[625,625,642],{"trials":672,"activeCount":63},[673],{"nctId":646,"briefTitle":647,"status":69,"phases":674,"primaryCompletion":649,"completion":650,"start":651,"enrollment":652,"conditions":675,"interventions":676},[54],[640],[625,642],{"trials":678,"activeCount":63},[],{"trials":680,"activeCount":63},[],{"intervention":544,"totalTrials":12,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":689,"PHASE4":695,"NA":697},{"trials":684,"activeCount":63},[],{"trials":686,"activeCount":63},[],{"trials":688,"activeCount":63},[],{"trials":690,"activeCount":63},[691],{"nctId":534,"briefTitle":535,"status":69,"phases":692,"primaryCompletion":537,"completion":538,"start":539,"enrollment":540,"conditions":693,"interventions":694},[54],[542],[544,497],{"trials":696,"activeCount":63},[],{"trials":698,"activeCount":63},[],{"intervention":619,"totalTrials":12,"cells":700},{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":707,"PHASE4":713,"NA":715},{"trials":702,"activeCount":63},[],{"trials":704,"activeCount":63},[],{"trials":706,"activeCount":63},[],{"trials":708,"activeCount":63},[709],{"nctId":610,"briefTitle":611,"status":453,"phases":710,"primaryCompletion":613,"completion":614,"start":615,"enrollment":616,"conditions":711,"interventions":712},[54],[24],[619,588],{"trials":714,"activeCount":63},[],{"trials":716,"activeCount":63},[],{"intervention":718,"totalTrials":9,"cells":719},"ACT-541468",{"EARLY_PHASE1":720,"PHASE1":722,"PHASE2":842,"PHASE3":854,"PHASE4":856,"NA":858},{"trials":721,"activeCount":63},[],{"trials":723,"activeCount":63},[724,732,742,750,760,768,777,787,799,807,815,825,834],{"nctId":725,"briefTitle":726,"status":69,"phases":727,"primaryCompletion":728,"completion":728,"start":729,"enrollment":163,"conditions":730,"interventions":731},"NCT03339752","A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin",[52],"2017-12-02","2017-10-30",[15],[156,718],{"nctId":733,"briefTitle":734,"status":69,"phases":735,"primaryCompletion":736,"completion":736,"start":737,"enrollment":738,"conditions":739,"interventions":741},"NCT03765294","A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea",[52],"2019-11-05","2019-03-14",28,[740],"Obstructive Sleep Apnea",[718],{"nctId":743,"briefTitle":744,"status":69,"phases":745,"primaryCompletion":332,"completion":332,"start":746,"enrollment":747,"conditions":748,"interventions":749},"NCT03609775","A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects",[52],"2018-08-28",22,[18],[718],{"nctId":751,"briefTitle":752,"status":69,"phases":753,"primaryCompletion":754,"completion":755,"start":756,"enrollment":757,"conditions":758,"interventions":759},"NCT03101189","A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects",[52],"2017-04-24","2017-04-26","2017-03-15",40,[15],[718],{"nctId":761,"briefTitle":762,"status":69,"phases":763,"primaryCompletion":90,"completion":90,"start":764,"enrollment":765,"conditions":766,"interventions":767},"NCT02571855","A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects",[52],"2015-10-01",85,[15],[718,718],{"nctId":769,"briefTitle":770,"status":69,"phases":771,"primaryCompletion":772,"completion":772,"start":773,"enrollment":9,"conditions":774,"interventions":775},"NCT02526888","Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects",[52],"2015-11-01","2015-09-01",[15],[718,776],"Diltiazem",{"nctId":778,"briefTitle":779,"status":69,"phases":780,"primaryCompletion":781,"completion":781,"start":782,"enrollment":783,"conditions":784,"interventions":786},"NCT04024332","Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects",[52],"2020-08-14","2019-09-24",16,[785,18],"Renal Insufficiency",[718],{"nctId":788,"briefTitle":789,"status":69,"phases":790,"primaryCompletion":791,"completion":791,"start":792,"enrollment":793,"conditions":794,"interventions":796},"NCT03657355","Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users",[52],"2019-08-08","2018-09-07",63,[795],"Healthy Recreational Drug Users",[718,797,798],"Suvorexant","Zolpidem",{"nctId":800,"briefTitle":801,"status":69,"phases":802,"primaryCompletion":803,"completion":803,"start":804,"enrollment":163,"conditions":805,"interventions":806},"NCT03799978","A Clinical Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects",[52],"2019-03-18","2019-03-09",[18],[718],{"nctId":808,"briefTitle":809,"status":69,"phases":810,"primaryCompletion":811,"completion":811,"start":91,"enrollment":757,"conditions":812,"interventions":813},"NCT02919319","A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects",[52],"2015-05-01",[15],[718,718,814],"14C-labeled ACT-541468",{"nctId":816,"briefTitle":817,"status":69,"phases":818,"primaryCompletion":819,"completion":819,"start":820,"enrollment":821,"conditions":822,"interventions":823},"NCT03892902","A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects",[52],"2019-10-10","2019-03-25",56,[18],[718,824],"Zopiclone 7.5 mg",{"nctId":826,"briefTitle":827,"status":69,"phases":828,"primaryCompletion":829,"completion":829,"start":830,"enrollment":738,"conditions":831,"interventions":833},"NCT03646864","A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease",[52],"2019-09-19","2018-11-15",[832],"Chronic Obstructive Pulmonary Disease",[718],{"nctId":835,"briefTitle":836,"status":69,"phases":837,"primaryCompletion":838,"completion":838,"start":839,"enrollment":163,"conditions":840,"interventions":841},"NCT03017495","A Clinical Study to Investigate the Potential Interactions Between Food and ACT-541468 and Between ACT-541468 and Midazolam",[52],"2017-02-01","2017-01-01",[15],[177,718],{"trials":843,"activeCount":63},[844],{"nctId":845,"briefTitle":846,"status":69,"phases":847,"primaryCompletion":848,"completion":849,"start":850,"enrollment":851,"conditions":852,"interventions":853},"NCT02841709","Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder",[53],"2017-05-31","2017-06-29","2016-11-28",58,[21],[718],{"trials":855,"activeCount":63},[],{"trials":857,"activeCount":63},[],{"trials":859,"activeCount":63},[],{"intervention":798,"totalTrials":8,"cells":861},{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":870,"PHASE3":895,"PHASE4":897,"NA":899},{"trials":863,"activeCount":63},[],{"trials":865,"activeCount":63},[866],{"nctId":788,"briefTitle":789,"status":69,"phases":867,"primaryCompletion":791,"completion":791,"start":792,"enrollment":793,"conditions":868,"interventions":869},[52],[795],[718,797,798],{"trials":871,"activeCount":63},[872,885],{"nctId":873,"briefTitle":874,"status":69,"phases":875,"primaryCompletion":876,"completion":877,"start":878,"enrollment":879,"conditions":880,"interventions":881},"NCT02839200","Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder",[53],"2017-04-12","2017-06-20","2016-10-04",360,[21],[882,883,884,798],"ACT-541468 5 mg","ACT-541468 10 mg","ACT-541468 25 mg",{"nctId":886,"briefTitle":887,"status":69,"phases":888,"primaryCompletion":889,"completion":890,"start":891,"enrollment":892,"conditions":893,"interventions":894},"NCT03056053","Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder",[53],"2017-04-21","2017-05-05","2017-02-15",113,[21],[798],{"trials":896,"activeCount":63},[],{"trials":898,"activeCount":63},[],{"trials":900,"activeCount":63},[],{"intervention":884,"totalTrials":30,"cells":902},{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":917,"PHASE3":923,"PHASE4":925,"NA":927},{"trials":904,"activeCount":63},[],{"trials":906,"activeCount":63},[907],{"nctId":908,"briefTitle":909,"status":69,"phases":910,"primaryCompletion":911,"completion":911,"start":912,"enrollment":913,"conditions":914,"interventions":916},"NCT03713242","A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment",[52],"2020-02-27","2018-02-26",32,[915],"Hepatic Impairment",[884,884],{"trials":918,"activeCount":63},[919],{"nctId":873,"briefTitle":874,"status":69,"phases":920,"primaryCompletion":876,"completion":877,"start":878,"enrollment":879,"conditions":921,"interventions":922},[53],[21],[882,883,884,798],{"trials":924,"activeCount":63},[],{"trials":926,"activeCount":63},[],{"trials":928,"activeCount":63},[],{"intervention":930,"totalTrials":30,"cells":931},"ACT-539313",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":946,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":933,"activeCount":63},[],{"trials":935,"activeCount":63},[936],{"nctId":937,"briefTitle":938,"status":69,"phases":939,"primaryCompletion":940,"completion":940,"start":941,"enrollment":747,"conditions":942,"interventions":943},"NCT05254548","A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects",[52],"2022-04-13","2022-02-18",[18],[930,944,945,177],"Flurbiprofen","Omeprazole",{"trials":947,"activeCount":63},[948],{"nctId":949,"briefTitle":950,"status":69,"phases":951,"primaryCompletion":952,"completion":953,"start":954,"enrollment":955,"conditions":956,"interventions":958},"NCT04753164","Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder",[53],"2022-03-21","2022-03-25","2021-02-16",136,[957],"Binge-Eating Disorder",[930],{"trials":960,"activeCount":63},[],{"trials":962,"activeCount":63},[],{"trials":964,"activeCount":63},[],{"intervention":605,"totalTrials":12,"cells":966},{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":968,"activeCount":63},[],{"trials":970,"activeCount":63},[],{"trials":972,"activeCount":63},[973],{"nctId":597,"briefTitle":598,"status":69,"phases":974,"primaryCompletion":600,"completion":600,"start":601,"enrollment":602,"conditions":975,"interventions":976},[53],[24],[605,606,588],{"trials":978,"activeCount":63},[],{"trials":980,"activeCount":63},[],{"trials":982,"activeCount":63},[],{"intervention":606,"totalTrials":12,"cells":984},{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":986,"activeCount":63},[],{"trials":988,"activeCount":63},[],{"trials":990,"activeCount":63},[991],{"nctId":597,"briefTitle":598,"status":69,"phases":992,"primaryCompletion":600,"completion":600,"start":601,"enrollment":602,"conditions":993,"interventions":994},[53],[24],[605,606,588],{"trials":996,"activeCount":63},[],{"trials":998,"activeCount":63},[],{"trials":1000,"activeCount":63},[],{"intervention":882,"totalTrials":12,"cells":1002},{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1007,"PHASE3":1013,"PHASE4":1015,"NA":1017},{"trials":1004,"activeCount":63},[],{"trials":1006,"activeCount":63},[],{"trials":1008,"activeCount":63},[1009],{"nctId":873,"briefTitle":874,"status":69,"phases":1010,"primaryCompletion":876,"completion":877,"start":878,"enrollment":879,"conditions":1011,"interventions":1012},[53],[21],[882,883,884,798],{"trials":1014,"activeCount":63},[],{"trials":1016,"activeCount":63},[],{"trials":1018,"activeCount":63},[],{"intervention":883,"totalTrials":12,"cells":1020},{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1031,"PHASE4":1033,"NA":1035},{"trials":1022,"activeCount":63},[],{"trials":1024,"activeCount":63},[],{"trials":1026,"activeCount":63},[1027],{"nctId":873,"briefTitle":874,"status":69,"phases":1028,"primaryCompletion":876,"completion":877,"start":878,"enrollment":879,"conditions":1029,"interventions":1030},[53],[21],[882,883,884,798],{"trials":1032,"activeCount":63},[],{"trials":1034,"activeCount":63},[],{"trials":1036,"activeCount":63},[],{"intervention":1038,"totalTrials":12,"cells":1039},"ACT-774312",{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1056,"PHASE4":1058,"NA":1060},{"trials":1041,"activeCount":63},[],{"trials":1043,"activeCount":63},[],{"trials":1045,"activeCount":63},[1046],{"nctId":1047,"briefTitle":1048,"status":69,"phases":1049,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":140,"conditions":1053,"interventions":1055},"NCT03688555","A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis",[53],"2020-11-24","2020-12-01","2018-10-19",[1054],"Bilateral Nasal Polyposis",[1038],{"trials":1057,"activeCount":63},[],{"trials":1059,"activeCount":63},[],{"trials":1061,"activeCount":63},[],{"intervention":1063,"totalTrials":12,"cells":1064},"ACT-050089",{"EARLY_PHASE1":1065,"PHASE1":1067,"PHASE2":1069,"PHASE3":1080,"PHASE4":1082,"NA":1084},{"trials":1066,"activeCount":63},[],{"trials":1068,"activeCount":63},[],{"trials":1070,"activeCount":63},[1071],{"nctId":1072,"briefTitle":1073,"status":453,"phases":1074,"primaryCompletion":1075,"completion":1076,"start":1077,"enrollment":30,"conditions":1078,"interventions":1079},"NCT01094067","Tezosentan in Patients With Pulmonary Arterial Hypertension",[53],"2010-12-01","2011-09-01","2010-09-01",[459],[1063],{"trials":1081,"activeCount":63},[],{"trials":1083,"activeCount":63},[],{"trials":1085,"activeCount":63},[],{"intervention":1087,"totalTrials":12,"cells":1088},"Setipiprant",{"EARLY_PHASE1":1089,"PHASE1":1091,"PHASE2":1093,"PHASE3":1106,"PHASE4":1108,"NA":1110},{"trials":1090,"activeCount":63},[],{"trials":1092,"activeCount":63},[],{"trials":1094,"activeCount":63},[1095],{"nctId":1096,"briefTitle":1097,"status":69,"phases":1098,"primaryCompletion":1099,"completion":1100,"start":1101,"enrollment":1102,"conditions":1103,"interventions":1105},"NCT01225315","Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma",[53],"2012-01-01","2012-02-01","2010-11-01",438,[1104],"Asthma",[1087],{"trials":1107,"activeCount":63},[],{"trials":1109,"activeCount":63},[],{"trials":1111,"activeCount":63},[],{"intervention":527,"totalTrials":12,"cells":1113},{"EARLY_PHASE1":1114,"PHASE1":1116,"PHASE2":1118,"PHASE3":1124,"PHASE4":1126,"NA":1128},{"trials":1115,"activeCount":63},[],{"trials":1117,"activeCount":63},[],{"trials":1119,"activeCount":63},[1120],{"nctId":517,"briefTitle":518,"status":69,"phases":1121,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":1122,"interventions":1123},[53],[525],[527,528,497,529,530],{"trials":1125,"activeCount":63},[],{"trials":1127,"activeCount":63},[],{"trials":1129,"activeCount":63},[],{"intervention":528,"totalTrials":12,"cells":1131},{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1142,"PHASE4":1144,"NA":1146},{"trials":1133,"activeCount":63},[],{"trials":1135,"activeCount":63},[],{"trials":1137,"activeCount":63},[1138],{"nctId":517,"briefTitle":518,"status":69,"phases":1139,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":1140,"interventions":1141},[53],[525],[527,528,497,529,530],{"trials":1143,"activeCount":63},[],{"trials":1145,"activeCount":63},[],{"trials":1147,"activeCount":63},[],{"intervention":529,"totalTrials":12,"cells":1149},{"EARLY_PHASE1":1150,"PHASE1":1152,"PHASE2":1154,"PHASE3":1160,"PHASE4":1162,"NA":1164},{"trials":1151,"activeCount":63},[],{"trials":1153,"activeCount":63},[],{"trials":1155,"activeCount":63},[1156],{"nctId":517,"briefTitle":518,"status":69,"phases":1157,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":1158,"interventions":1159},[53],[525],[527,528,497,529,530],{"trials":1161,"activeCount":63},[],{"trials":1163,"activeCount":63},[],{"trials":1165,"activeCount":63},[],{"intervention":530,"totalTrials":12,"cells":1167},{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1172,"PHASE3":1178,"PHASE4":1180,"NA":1182},{"trials":1169,"activeCount":63},[],{"trials":1171,"activeCount":63},[],{"trials":1173,"activeCount":63},[1174],{"nctId":517,"briefTitle":518,"status":69,"phases":1175,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":1176,"interventions":1177},[53],[525],[527,528,497,529,530],{"trials":1179,"activeCount":63},[],{"trials":1181,"activeCount":63},[],{"trials":1183,"activeCount":63},[],{"intervention":1185,"totalTrials":12,"cells":1186},"ACT-280778",{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1191,"PHASE3":1201,"PHASE4":1203,"NA":1205},{"trials":1188,"activeCount":63},[],{"trials":1190,"activeCount":63},[],{"trials":1192,"activeCount":63},[1193],{"nctId":1194,"briefTitle":525,"status":69,"phases":1195,"primaryCompletion":1196,"completion":649,"start":637,"enrollment":1197,"conditions":1198,"interventions":1199},"NCT01264692",[53],"2012-01",196,[525],[1185,1200],"Amlodipine",{"trials":1202,"activeCount":63},[],{"trials":1204,"activeCount":63},[],{"trials":1206,"activeCount":63},[],{"intervention":1200,"totalTrials":12,"cells":1208},{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1219,"PHASE4":1221,"NA":1223},{"trials":1210,"activeCount":63},[],{"trials":1212,"activeCount":63},[],{"trials":1214,"activeCount":63},[1215],{"nctId":1194,"briefTitle":525,"status":69,"phases":1216,"primaryCompletion":1196,"completion":649,"start":637,"enrollment":1197,"conditions":1217,"interventions":1218},[53],[525],[1185,1200],{"trials":1220,"activeCount":63},[],{"trials":1222,"activeCount":63},[],{"trials":1224,"activeCount":63},[],{"intervention":1226,"totalTrials":12,"cells":1227},"ACT-709478 for oral use",{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1243,"PHASE4":1245,"NA":1247},{"trials":1229,"activeCount":63},[],{"trials":1231,"activeCount":63},[],{"trials":1233,"activeCount":63},[1234],{"nctId":1235,"briefTitle":1236,"status":69,"phases":1237,"primaryCompletion":1238,"completion":1238,"start":1239,"enrollment":25,"conditions":1240,"interventions":1242},"NCT03239691","A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients",[53],"2018-04-25","2017-10-06",[1241],"Photosensitive Epilepsy",[1226],{"trials":1244,"activeCount":63},[],{"trials":1246,"activeCount":63},[],{"trials":1248,"activeCount":63},[],{"intervention":1250,"totalTrials":1251,"cells":1252},"Aprocitentan",6,{"EARLY_PHASE1":1253,"PHASE1":1255,"PHASE2":1312,"PHASE3":1314,"PHASE4":1316,"NA":1318},{"trials":1254,"activeCount":63},[],{"trials":1256,"activeCount":63},[1257,1266,1277,1285,1295,1303],{"nctId":1258,"briefTitle":1259,"status":69,"phases":1260,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":195,"conditions":1264,"interventions":1265},"NCT05196399","Bioequivalence Study of Different Aprocitentan Tablet Formulations",[52],"2022-03-27","2022-04-07","2022-02-02",[15],[1250,1250],{"nctId":1267,"briefTitle":1268,"status":69,"phases":1269,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1275},"NCT06799884","A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives",[52],"2025-02-21","2025-01-18",19,[1274],"Drug Drug Interaction",[1276,1250],"Ethinyl Estradiol \u002F Levonorgestrel Oral",{"nctId":1278,"briefTitle":1279,"status":69,"phases":1280,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":163,"conditions":1283,"interventions":1284},"NCT03245229","A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)",[52],"2017-09-18","2017-08-10",[15],[1250,156],{"nctId":1286,"briefTitle":1287,"status":69,"phases":1288,"primaryCompletion":1289,"completion":1290,"start":1291,"enrollment":163,"conditions":1292,"interventions":1293},"NCT02841761","A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects",[52],"2016-09-01","2016-10-01","2016-07-01",[15],[1294,1250],"Midalozam",{"nctId":1296,"briefTitle":1297,"status":69,"phases":1298,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":152,"conditions":1301,"interventions":1302},"NCT02708004","Clinical Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects",[52],"2016-12-01","2016-06-01",[15],[1250],{"nctId":1304,"briefTitle":1305,"status":69,"phases":1306,"primaryCompletion":1307,"completion":1308,"start":183,"enrollment":1309,"conditions":1310,"interventions":1311},"NCT04252495","The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics",[52],"2021-04-05","2021-05-06",17,[915,15],[1250],{"trials":1313,"activeCount":63},[],{"trials":1315,"activeCount":63},[],{"trials":1317,"activeCount":63},[],{"trials":1319,"activeCount":63},[],{"intervention":177,"totalTrials":25,"cells":1321},{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1358,"PHASE3":1360,"PHASE4":1362,"NA":1364},{"trials":1323,"activeCount":63},[],{"trials":1325,"activeCount":63},[1326,1330,1334,1345,1354],{"nctId":937,"briefTitle":938,"status":69,"phases":1327,"primaryCompletion":940,"completion":940,"start":941,"enrollment":747,"conditions":1328,"interventions":1329},[52],[18],[930,944,945,177],{"nctId":168,"briefTitle":169,"status":69,"phases":1331,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":1332,"interventions":1333},[52],[18],[177,178,40],{"nctId":1335,"briefTitle":1336,"status":69,"phases":1337,"primaryCompletion":830,"completion":1338,"start":1339,"enrollment":1340,"conditions":1341,"interventions":1342},"NCT03165097","Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy Subjects",[52],"2018-12-28","2017-07-07",46,[15],[1343,177,1344],"ACT-709478","ACT-709478 combined with midazolam",{"nctId":1346,"briefTitle":1347,"status":69,"phases":1348,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":163,"conditions":1351,"interventions":1352},"NCT03363984","Pharmacokinetic Interaction Between Midazolam and ID-082 in Healthy Subjects",[52],"2017-12-19","2017-11-27",[18],[177,1353],"ID-082",{"nctId":835,"briefTitle":836,"status":69,"phases":1355,"primaryCompletion":838,"completion":838,"start":839,"enrollment":163,"conditions":1356,"interventions":1357},[52],[15],[177,718],{"trials":1359,"activeCount":63},[],{"trials":1361,"activeCount":63},[],{"trials":1363,"activeCount":63},[],{"trials":1365,"activeCount":63},[],{"intervention":156,"totalTrials":8,"cells":1367},{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1384,"PHASE3":1386,"PHASE4":1388,"NA":1390},{"trials":1369,"activeCount":63},[],{"trials":1371,"activeCount":63},[1372,1376,1380],{"nctId":725,"briefTitle":726,"status":69,"phases":1373,"primaryCompletion":728,"completion":728,"start":729,"enrollment":163,"conditions":1374,"interventions":1375},[52],[15],[156,718],{"nctId":147,"briefTitle":148,"status":69,"phases":1377,"primaryCompletion":150,"completion":150,"start":151,"enrollment":152,"conditions":1378,"interventions":1379},[52],[18],[155,156,40],{"nctId":1278,"briefTitle":1279,"status":69,"phases":1381,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":163,"conditions":1382,"interventions":1383},[52],[15],[1250,156],{"trials":1385,"activeCount":63},[],{"trials":1387,"activeCount":63},[],{"trials":1389,"activeCount":63},[],{"trials":1391,"activeCount":63},[],{"intervention":76,"totalTrials":8,"cells":1393},{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1410,"PHASE3":1412,"PHASE4":1414,"NA":1416},{"trials":1395,"activeCount":63},[],{"trials":1397,"activeCount":63},[1398,1402,1406],{"nctId":67,"briefTitle":68,"status":69,"phases":1399,"primaryCompletion":71,"completion":71,"start":72,"enrollment":73,"conditions":1400,"interventions":1401},[52],[18],[45,76,45,45],{"nctId":190,"briefTitle":191,"status":69,"phases":1403,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":1404,"interventions":1405},[52],[18],[40,76],{"nctId":367,"briefTitle":368,"status":69,"phases":1407,"primaryCompletion":370,"completion":370,"start":371,"enrollment":195,"conditions":1408,"interventions":1409},[52],[15],[351,76],{"trials":1411,"activeCount":63},[],{"trials":1413,"activeCount":63},[],{"trials":1415,"activeCount":63},[],{"trials":1417,"activeCount":63},[],{"intervention":1419,"totalTrials":8,"cells":1420},"ACT-1004-1239",{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1451,"PHASE3":1453,"PHASE4":1455,"NA":1457},{"trials":1422,"activeCount":63},[],{"trials":1424,"activeCount":63},[1425,1434,1442],{"nctId":1426,"briefTitle":1427,"status":69,"phases":1428,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1431,"conditions":1432,"interventions":1433},"NCT04286750","Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239",[52],"2020-09-25","2020-07-11",50,[18],[1419],{"nctId":1435,"briefTitle":1436,"status":69,"phases":1437,"primaryCompletion":1438,"completion":1438,"start":820,"enrollment":1439,"conditions":1440,"interventions":1441},"NCT03869320","A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects",[52],"2019-07-11",64,[18],[1419,1419],{"nctId":1443,"briefTitle":1444,"status":69,"phases":1445,"primaryCompletion":1446,"completion":1446,"start":1447,"enrollment":783,"conditions":1448,"interventions":1449},"NCT05549531","A Study to Investigate the Effect of Itraconazole on the Way the Body Absorbs, Distributes, and Gets Rid of ACT-1004-1239 Given as a Single Dose of 10 mg to Healthy Male Subjects",[52],"2022-10-20","2022-10-01",[18],[1419,1450],"Itraconazole",{"trials":1452,"activeCount":63},[],{"trials":1454,"activeCount":63},[],{"trials":1456,"activeCount":63},[],{"trials":1458,"activeCount":63},[],{"intervention":1460,"totalTrials":30,"cells":1461},"ACT-389949 200 mg",{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1493,"PHASE3":1495,"PHASE4":1497,"NA":1499},{"trials":1463,"activeCount":63},[],{"trials":1465,"activeCount":63},[1466,1482],{"nctId":1467,"briefTitle":1468,"status":69,"phases":1469,"primaryCompletion":1470,"completion":1470,"start":1471,"enrollment":1472,"conditions":1473,"interventions":1474},"NCT02099071","Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949",[52],"2012-05","2011-11",65,[15],[1475,1476,1477,1478,1479,1460,1480,1481],"ACT-389949 1 mg","ACT-389949 5 mg","ACT-389949 20 mg","ACT-389949 50 mg","ACT-389949 100 mg","ACT-389949 500 mg","ACT-389949 1000 mg",{"nctId":1483,"briefTitle":1484,"status":69,"phases":1485,"primaryCompletion":1486,"completion":1486,"start":1487,"enrollment":1472,"conditions":1488,"interventions":1489},"NCT02099201","Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects",[52],"2013-05","2012-11",[15],[1490,1460,1491,1492,1492],"ACT-389949 40 mg","ACT-389949 800 mg","ACT-389949",{"trials":1494,"activeCount":63},[],{"trials":1496,"activeCount":63},[],{"trials":1498,"activeCount":63},[],{"trials":1500,"activeCount":63},[],{"intervention":1343,"totalTrials":30,"cells":1502},{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1519,"PHASE3":1521,"PHASE4":1523,"NA":1525},{"trials":1504,"activeCount":63},[],{"trials":1506,"activeCount":63},[1507,1515],{"nctId":1508,"briefTitle":1509,"status":69,"phases":1510,"primaryCompletion":1511,"completion":1511,"start":1512,"enrollment":163,"conditions":1513,"interventions":1514},"NCT04123288","A Study to Compare a Single-dose of Two Different Formulations of ACT-709478 in Healthy Men",[52],"2020-02-05","2019-12-16",[15],[1343,1343],{"nctId":1335,"briefTitle":1336,"status":69,"phases":1516,"primaryCompletion":830,"completion":1338,"start":1339,"enrollment":1340,"conditions":1517,"interventions":1518},[52],[15],[1343,177,1344],{"trials":1520,"activeCount":63},[],{"trials":1522,"activeCount":63},[],{"trials":1524,"activeCount":63},[],{"trials":1526,"activeCount":63},[],{"intervention":1528,"totalTrials":30,"cells":1529},"ID-085",{"EARLY_PHASE1":1530,"PHASE1":1532,"PHASE2":1552,"PHASE3":1554,"PHASE4":1556,"NA":1558},{"trials":1531,"activeCount":63},[],{"trials":1533,"activeCount":63},[1534,1543],{"nctId":1535,"briefTitle":1536,"status":69,"phases":1537,"primaryCompletion":1538,"completion":1538,"start":1539,"enrollment":913,"conditions":1540,"interventions":1542},"NCT03913000","A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease",[52],"2019-08-22","2019-04-29",[1541],"Renal Impairment",[1528],{"nctId":1544,"briefTitle":1545,"status":69,"phases":1546,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":1549,"conditions":1550,"interventions":1551},"NCT03372629","A Study to Evaluate if ID-085 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects",[52],"2018-12-02","2018-01-12",88,[15],[1528],{"trials":1553,"activeCount":63},[],{"trials":1555,"activeCount":63},[],{"trials":1557,"activeCount":63},[],{"trials":1559,"activeCount":63},[],{"intervention":1561,"totalTrials":30,"cells":1562},"ACT-1014-6470",{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1585,"PHASE3":1587,"PHASE4":1589,"NA":1591},{"trials":1564,"activeCount":63},[],{"trials":1566,"activeCount":63},[1567,1575],{"nctId":1568,"briefTitle":1569,"status":69,"phases":1570,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":1340,"conditions":1573,"interventions":1574},"NCT04608513","A Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects",[52],"2021-09-20","2020-11-16",[18],[1561],{"nctId":1576,"briefTitle":1577,"status":69,"phases":1578,"primaryCompletion":1579,"completion":1579,"start":1580,"enrollment":1549,"conditions":1581,"interventions":1582},"NCT04183686","A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects",[52],"2020-03-15","2019-11-25",[18],[1561,1561,1583,1584],"14C-ACT-1014-6470 microtracer","14C-ACT-1014-6470 microtracer placebo",{"trials":1586,"activeCount":63},[],{"trials":1588,"activeCount":63},[],{"trials":1590,"activeCount":63},[],{"trials":1592,"activeCount":63},[],{"intervention":1594,"totalTrials":12,"cells":1595},"ACT-132577",{"EARLY_PHASE1":1596,"PHASE1":1598,"PHASE2":1609,"PHASE3":1611,"PHASE4":1613,"NA":1615},{"trials":1597,"activeCount":63},[],{"trials":1599,"activeCount":63},[1600],{"nctId":1601,"briefTitle":1602,"status":69,"phases":1603,"primaryCompletion":1604,"completion":1604,"start":1605,"enrollment":783,"conditions":1606,"interventions":1608},"NCT03165071","A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease",[52],"2017-10-27","2017-06-03",[1607,15],"Severe Renal Impairment",[1594],{"trials":1610,"activeCount":63},[],{"trials":1612,"activeCount":63},[],{"trials":1614,"activeCount":63},[],{"trials":1616,"activeCount":63},[],{"intervention":1475,"totalTrials":12,"cells":1618},{"EARLY_PHASE1":1619,"PHASE1":1621,"PHASE2":1627,"PHASE3":1629,"PHASE4":1631,"NA":1633},{"trials":1620,"activeCount":63},[],{"trials":1622,"activeCount":63},[1623],{"nctId":1467,"briefTitle":1468,"status":69,"phases":1624,"primaryCompletion":1470,"completion":1470,"start":1471,"enrollment":1472,"conditions":1625,"interventions":1626},[52],[15],[1475,1476,1477,1478,1479,1460,1480,1481],{"trials":1628,"activeCount":63},[],{"trials":1630,"activeCount":63},[],{"trials":1632,"activeCount":63},[],{"trials":1634,"activeCount":63},[],{"intervention":1476,"totalTrials":12,"cells":1636},{"EARLY_PHASE1":1637,"PHASE1":1639,"PHASE2":1645,"PHASE3":1647,"PHASE4":1649,"NA":1651},{"trials":1638,"activeCount":63},[],{"trials":1640,"activeCount":63},[1641],{"nctId":1467,"briefTitle":1468,"status":69,"phases":1642,"primaryCompletion":1470,"completion":1470,"start":1471,"enrollment":1472,"conditions":1643,"interventions":1644},[52],[15],[1475,1476,1477,1478,1479,1460,1480,1481],{"trials":1646,"activeCount":63},[],{"trials":1648,"activeCount":63},[],{"trials":1650,"activeCount":63},[],{"trials":1652,"activeCount":63},[],{"intervention":1477,"totalTrials":12,"cells":1654},{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1663,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1656,"activeCount":63},[],{"trials":1658,"activeCount":63},[1659],{"nctId":1467,"briefTitle":1468,"status":69,"phases":1660,"primaryCompletion":1470,"completion":1470,"start":1471,"enrollment":1472,"conditions":1661,"interventions":1662},[52],[15],[1475,1476,1477,1478,1479,1460,1480,1481],{"trials":1664,"activeCount":63},[],{"trials":1666,"activeCount":63},[],{"trials":1668,"activeCount":63},[],{"trials":1670,"activeCount":63},[],{"intervention":1478,"totalTrials":12,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1681,"PHASE3":1683,"PHASE4":1685,"NA":1687},{"trials":1674,"activeCount":63},[],{"trials":1676,"activeCount":63},[1677],{"nctId":1467,"briefTitle":1468,"status":69,"phases":1678,"primaryCompletion":1470,"completion":1470,"start":1471,"enrollment":1472,"conditions":1679,"interventions":1680},[52],[15],[1475,1476,1477,1478,1479,1460,1480,1481],{"trials":1682,"activeCount":63},[],{"trials":1684,"activeCount":63},[],{"trials":1686,"activeCount":63},[],{"trials":1688,"activeCount":63},[],{"intervention":1479,"totalTrials":12,"cells":1690},{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1699,"PHASE3":1701,"PHASE4":1703,"NA":1705},{"trials":1692,"activeCount":63},[],{"trials":1694,"activeCount":63},[1695],{"nctId":1467,"briefTitle":1468,"status":69,"phases":1696,"primaryCompletion":1470,"completion":1470,"start":1471,"enrollment":1472,"conditions":1697,"interventions":1698},[52],[15],[1475,1476,1477,1478,1479,1460,1480,1481],{"trials":1700,"activeCount":63},[],{"trials":1702,"activeCount":63},[],{"trials":1704,"activeCount":63},[],{"trials":1706,"activeCount":63},[],{"intervention":1480,"totalTrials":12,"cells":1708},{"EARLY_PHASE1":1709,"PHASE1":1711,"PHASE2":1717,"PHASE3":1719,"PHASE4":1721,"NA":1723},{"trials":1710,"activeCount":63},[],{"trials":1712,"activeCount":63},[1713],{"nctId":1467,"briefTitle":1468,"status":69,"phases":1714,"primaryCompletion":1470,"completion":1470,"start":1471,"enrollment":1472,"conditions":1715,"interventions":1716},[52],[15],[1475,1476,1477,1478,1479,1460,1480,1481],{"trials":1718,"activeCount":63},[],{"trials":1720,"activeCount":63},[],{"trials":1722,"activeCount":63},[],{"trials":1724,"activeCount":63},[],{"intervention":1481,"totalTrials":12,"cells":1726},{"EARLY_PHASE1":1727,"PHASE1":1729,"PHASE2":1735,"PHASE3":1737,"PHASE4":1739,"NA":1741},{"trials":1728,"activeCount":63},[],{"trials":1730,"activeCount":63},[1731],{"nctId":1467,"briefTitle":1468,"status":69,"phases":1732,"primaryCompletion":1470,"completion":1470,"start":1471,"enrollment":1472,"conditions":1733,"interventions":1734},[52],[15],[1475,1476,1477,1478,1479,1460,1480,1481],{"trials":1736,"activeCount":63},[],{"trials":1738,"activeCount":63},[],{"trials":1740,"activeCount":63},[],{"trials":1742,"activeCount":63},[],{"intervention":1744,"totalTrials":12,"cells":1745},"AC-083",{"EARLY_PHASE1":1746,"PHASE1":1748,"PHASE2":1758,"PHASE3":1760,"PHASE4":1762,"NA":1764},{"trials":1747,"activeCount":63},[],{"trials":1749,"activeCount":63},[1750],{"nctId":1751,"briefTitle":1752,"status":69,"phases":1753,"primaryCompletion":1299,"completion":1299,"start":1754,"enrollment":1755,"conditions":1756,"interventions":1757},"NCT02719197","First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders",[52],"2016-02-19",72,[15],[1744],{"trials":1759,"activeCount":63},[],{"trials":1761,"activeCount":63},[],{"trials":1763,"activeCount":63},[],{"trials":1765,"activeCount":63},[],{"intervention":1767,"totalTrials":12,"cells":1768},"ACT-453859 1 mg",{"EARLY_PHASE1":1769,"PHASE1":1771,"PHASE2":1788,"PHASE3":1790,"PHASE4":1792,"NA":1794},{"trials":1770,"activeCount":63},[],{"trials":1772,"activeCount":63},[1773],{"nctId":1774,"briefTitle":1775,"status":69,"phases":1776,"primaryCompletion":1777,"completion":1777,"start":651,"enrollment":1549,"conditions":1778,"interventions":1779},"NCT02381496","A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)",[52],"2012-04",[18],[1767,1780,1781,1782,1783,1784,1785,1786,1787],"ACT-453859 3 mg","ACT-453859 10 mg","ACT-453859 30mg","ACT-453859 100 mg","ACT-453859 300 mg","ACT-453859 800 mg","Setipiprant 500 mg","Setipiprant 1000 mg",{"trials":1789,"activeCount":63},[],{"trials":1791,"activeCount":63},[],{"trials":1793,"activeCount":63},[],{"trials":1795,"activeCount":63},[],{"intervention":1780,"totalTrials":12,"cells":1797},{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1806,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1799,"activeCount":63},[],{"trials":1801,"activeCount":63},[1802],{"nctId":1774,"briefTitle":1775,"status":69,"phases":1803,"primaryCompletion":1777,"completion":1777,"start":651,"enrollment":1549,"conditions":1804,"interventions":1805},[52],[18],[1767,1780,1781,1782,1783,1784,1785,1786,1787],{"trials":1807,"activeCount":63},[],{"trials":1809,"activeCount":63},[],{"trials":1811,"activeCount":63},[],{"trials":1813,"activeCount":63},[],{"intervention":1781,"totalTrials":12,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1824,"PHASE3":1826,"PHASE4":1828,"NA":1830},{"trials":1817,"activeCount":63},[],{"trials":1819,"activeCount":63},[1820],{"nctId":1774,"briefTitle":1775,"status":69,"phases":1821,"primaryCompletion":1777,"completion":1777,"start":651,"enrollment":1549,"conditions":1822,"interventions":1823},[52],[18],[1767,1780,1781,1782,1783,1784,1785,1786,1787],{"trials":1825,"activeCount":63},[],{"trials":1827,"activeCount":63},[],{"trials":1829,"activeCount":63},[],{"trials":1831,"activeCount":63},[],{"intervention":1782,"totalTrials":12,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1842,"PHASE3":1844,"PHASE4":1846,"NA":1848},{"trials":1835,"activeCount":63},[],{"trials":1837,"activeCount":63},[1838],{"nctId":1774,"briefTitle":1775,"status":69,"phases":1839,"primaryCompletion":1777,"completion":1777,"start":651,"enrollment":1549,"conditions":1840,"interventions":1841},[52],[18],[1767,1780,1781,1782,1783,1784,1785,1786,1787],{"trials":1843,"activeCount":63},[],{"trials":1845,"activeCount":63},[],{"trials":1847,"activeCount":63},[],{"trials":1849,"activeCount":63},[],{"intervention":1783,"totalTrials":12,"cells":1851},{"EARLY_PHASE1":1852,"PHASE1":1854,"PHASE2":1860,"PHASE3":1862,"PHASE4":1864,"NA":1866},{"trials":1853,"activeCount":63},[],{"trials":1855,"activeCount":63},[1856],{"nctId":1774,"briefTitle":1775,"status":69,"phases":1857,"primaryCompletion":1777,"completion":1777,"start":651,"enrollment":1549,"conditions":1858,"interventions":1859},[52],[18],[1767,1780,1781,1782,1783,1784,1785,1786,1787],{"trials":1861,"activeCount":63},[],{"trials":1863,"activeCount":63},[],{"trials":1865,"activeCount":63},[],{"trials":1867,"activeCount":63},[],{"intervention":1784,"totalTrials":12,"cells":1869},{"EARLY_PHASE1":1870,"PHASE1":1872,"PHASE2":1878,"PHASE3":1880,"PHASE4":1882,"NA":1884},{"trials":1871,"activeCount":63},[],{"trials":1873,"activeCount":63},[1874],{"nctId":1774,"briefTitle":1775,"status":69,"phases":1875,"primaryCompletion":1777,"completion":1777,"start":651,"enrollment":1549,"conditions":1876,"interventions":1877},[52],[18],[1767,1780,1781,1782,1783,1784,1785,1786,1787],{"trials":1879,"activeCount":63},[],{"trials":1881,"activeCount":63},[],{"trials":1883,"activeCount":63},[],{"trials":1885,"activeCount":63},[],{"intervention":1785,"totalTrials":12,"cells":1887},{"EARLY_PHASE1":1888,"PHASE1":1890,"PHASE2":1896,"PHASE3":1898,"PHASE4":1900,"NA":1902},{"trials":1889,"activeCount":63},[],{"trials":1891,"activeCount":63},[1892],{"nctId":1774,"briefTitle":1775,"status":69,"phases":1893,"primaryCompletion":1777,"completion":1777,"start":651,"enrollment":1549,"conditions":1894,"interventions":1895},[52],[18],[1767,1780,1781,1782,1783,1784,1785,1786,1787],{"trials":1897,"activeCount":63},[],{"trials":1899,"activeCount":63},[],{"trials":1901,"activeCount":63},[],{"trials":1903,"activeCount":63},[],{"intervention":1786,"totalTrials":12,"cells":1905},{"EARLY_PHASE1":1906,"PHASE1":1908,"PHASE2":1914,"PHASE3":1916,"PHASE4":1918,"NA":1920},{"trials":1907,"activeCount":63},[],{"trials":1909,"activeCount":63},[1910],{"nctId":1774,"briefTitle":1775,"status":69,"phases":1911,"primaryCompletion":1777,"completion":1777,"start":651,"enrollment":1549,"conditions":1912,"interventions":1913},[52],[18],[1767,1780,1781,1782,1783,1784,1785,1786,1787],{"trials":1915,"activeCount":63},[],{"trials":1917,"activeCount":63},[],{"trials":1919,"activeCount":63},[],{"trials":1921,"activeCount":63},[],{"intervention":1787,"totalTrials":12,"cells":1923},{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1932,"PHASE3":1934,"PHASE4":1936,"NA":1938},{"trials":1925,"activeCount":63},[],{"trials":1927,"activeCount":63},[1928],{"nctId":1774,"briefTitle":1775,"status":69,"phases":1929,"primaryCompletion":1777,"completion":1777,"start":651,"enrollment":1549,"conditions":1930,"interventions":1931},[52],[18],[1767,1780,1781,1782,1783,1784,1785,1786,1787],{"trials":1933,"activeCount":63},[],{"trials":1935,"activeCount":63},[],{"trials":1937,"activeCount":63},[],{"trials":1939,"activeCount":63},[],{"intervention":155,"totalTrials":12,"cells":1941},{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1950,"PHASE3":1952,"PHASE4":1954,"NA":1956},{"trials":1943,"activeCount":63},[],{"trials":1945,"activeCount":63},[1946],{"nctId":147,"briefTitle":148,"status":69,"phases":1947,"primaryCompletion":150,"completion":150,"start":151,"enrollment":152,"conditions":1948,"interventions":1949},[52],[18],[155,156,40],{"trials":1951,"activeCount":63},[],{"trials":1953,"activeCount":63},[],{"trials":1955,"activeCount":63},[],{"trials":1957,"activeCount":63},[],{"intervention":1959,"totalTrials":12,"cells":1960},"ACT-129968 500 mg",{"EARLY_PHASE1":1961,"PHASE1":1963,"PHASE2":1973,"PHASE3":1975,"PHASE4":1977,"NA":1979},{"trials":1962,"activeCount":63},[],{"trials":1964,"activeCount":63},[1965],{"nctId":1966,"briefTitle":1967,"status":69,"phases":1968,"primaryCompletion":1969,"completion":1969,"start":1969,"enrollment":163,"conditions":1970,"interventions":1971},"NCT01877629","Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy Subjects",[52],"2011-07-01",[15],[1959,1972],"ACT-129968 250 mg",{"trials":1974,"activeCount":63},[],{"trials":1976,"activeCount":63},[],{"trials":1978,"activeCount":63},[],{"trials":1980,"activeCount":63},[],{"intervention":1972,"totalTrials":12,"cells":1982},{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":1991,"PHASE3":1993,"PHASE4":1995,"NA":1997},{"trials":1984,"activeCount":63},[],{"trials":1986,"activeCount":63},[1987],{"nctId":1966,"briefTitle":1967,"status":69,"phases":1988,"primaryCompletion":1969,"completion":1969,"start":1969,"enrollment":163,"conditions":1989,"interventions":1990},[52],[15],[1959,1972],{"trials":1992,"activeCount":63},[],{"trials":1994,"activeCount":63},[],{"trials":1996,"activeCount":63},[],{"trials":1998,"activeCount":63},[],{"intervention":944,"totalTrials":12,"cells":2000},{"EARLY_PHASE1":2001,"PHASE1":2003,"PHASE2":2009,"PHASE3":2011,"PHASE4":2013,"NA":2015},{"trials":2002,"activeCount":63},[],{"trials":2004,"activeCount":63},[2005],{"nctId":937,"briefTitle":938,"status":69,"phases":2006,"primaryCompletion":940,"completion":940,"start":941,"enrollment":747,"conditions":2007,"interventions":2008},[52],[18],[930,944,945,177],{"trials":2010,"activeCount":63},[],{"trials":2012,"activeCount":63},[],{"trials":2014,"activeCount":63},[],{"trials":2016,"activeCount":63},[],{"intervention":945,"totalTrials":12,"cells":2018},{"EARLY_PHASE1":2019,"PHASE1":2021,"PHASE2":2027,"PHASE3":2029,"PHASE4":2031,"NA":2033},{"trials":2020,"activeCount":63},[],{"trials":2022,"activeCount":63},[2023],{"nctId":937,"briefTitle":938,"status":69,"phases":2024,"primaryCompletion":940,"completion":940,"start":941,"enrollment":747,"conditions":2025,"interventions":2026},[52],[18],[930,944,945,177],{"trials":2028,"activeCount":63},[],{"trials":2030,"activeCount":63},[],{"trials":2032,"activeCount":63},[],{"trials":2034,"activeCount":63},[],{"intervention":2036,"totalTrials":12,"cells":2037},"5 mg ACT-281959 prodrug formulation I",{"EARLY_PHASE1":2038,"PHASE1":2040,"PHASE2":2055,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2039,"activeCount":63},[],{"trials":2041,"activeCount":63},[2042],{"nctId":2043,"briefTitle":2044,"status":69,"phases":2045,"primaryCompletion":650,"completion":650,"start":2046,"enrollment":2047,"conditions":2048,"interventions":2050},"NCT01954615","Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 \u002F ACT-246475 in Healthy Male Subjects",[52],"2011-10",49,[2049],"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics",[2036,2051,2052,2053,2054],"20 mg ACT-281959 prodrug formulation I","ACT-281959 prodrug formulation I","ACT-281959 prodrug formulation II","ACT-246475",{"trials":2056,"activeCount":63},[],{"trials":2058,"activeCount":63},[],{"trials":2060,"activeCount":63},[],{"trials":2062,"activeCount":63},[],{"intervention":2051,"totalTrials":12,"cells":2064},{"EARLY_PHASE1":2065,"PHASE1":2067,"PHASE2":2073,"PHASE3":2075,"PHASE4":2077,"NA":2079},{"trials":2066,"activeCount":63},[],{"trials":2068,"activeCount":63},[2069],{"nctId":2043,"briefTitle":2044,"status":69,"phases":2070,"primaryCompletion":650,"completion":650,"start":2046,"enrollment":2047,"conditions":2071,"interventions":2072},[52],[2049],[2036,2051,2052,2053,2054],{"trials":2074,"activeCount":63},[],{"trials":2076,"activeCount":63},[],{"trials":2078,"activeCount":63},[],{"trials":2080,"activeCount":63},[],{"intervention":2052,"totalTrials":12,"cells":2082},{"EARLY_PHASE1":2083,"PHASE1":2085,"PHASE2":2091,"PHASE3":2093,"PHASE4":2095,"NA":2097},{"trials":2084,"activeCount":63},[],{"trials":2086,"activeCount":63},[2087],{"nctId":2043,"briefTitle":2044,"status":69,"phases":2088,"primaryCompletion":650,"completion":650,"start":2046,"enrollment":2047,"conditions":2089,"interventions":2090},[52],[2049],[2036,2051,2052,2053,2054],{"trials":2092,"activeCount":63},[],{"trials":2094,"activeCount":63},[],{"trials":2096,"activeCount":63},[],{"trials":2098,"activeCount":63},[],{"intervention":2053,"totalTrials":12,"cells":2100},{"EARLY_PHASE1":2101,"PHASE1":2103,"PHASE2":2109,"PHASE3":2111,"PHASE4":2113,"NA":2115},{"trials":2102,"activeCount":63},[],{"trials":2104,"activeCount":63},[2105],{"nctId":2043,"briefTitle":2044,"status":69,"phases":2106,"primaryCompletion":650,"completion":650,"start":2046,"enrollment":2047,"conditions":2107,"interventions":2108},[52],[2049],[2036,2051,2052,2053,2054],{"trials":2110,"activeCount":63},[],{"trials":2112,"activeCount":63},[],{"trials":2114,"activeCount":63},[],{"trials":2116,"activeCount":63},[],{"intervention":2054,"totalTrials":12,"cells":2118},{"EARLY_PHASE1":2119,"PHASE1":2121,"PHASE2":2127,"PHASE3":2129,"PHASE4":2131,"NA":2133},{"trials":2120,"activeCount":63},[],{"trials":2122,"activeCount":63},[2123],{"nctId":2043,"briefTitle":2044,"status":69,"phases":2124,"primaryCompletion":650,"completion":650,"start":2046,"enrollment":2047,"conditions":2125,"interventions":2126},[52],[2049],[2036,2051,2052,2053,2054],{"trials":2128,"activeCount":63},[],{"trials":2130,"activeCount":63},[],{"trials":2132,"activeCount":63},[],{"trials":2134,"activeCount":63},[],{"intervention":2136,"totalTrials":12,"cells":2137},"ACT-541478 10 mg",{"EARLY_PHASE1":2138,"PHASE1":2140,"PHASE2":2156,"PHASE3":2158,"PHASE4":2160,"NA":2162},{"trials":2139,"activeCount":63},[],{"trials":2141,"activeCount":63},[2142],{"nctId":2143,"briefTitle":2144,"status":453,"phases":2145,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":821,"conditions":2148,"interventions":2149},"NCT04452006","A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478",[52],"2021-04-20","2020-07-20",[18],[2136,2150,2151,2152,2153,2154,2155],"ACT-541478 30 mg","ACT-541478 100 mg","ACT-541478 300 mg","ACT-541478 1000 mg","ACT-541478 high or low dose","ACT-541478 dose E1",{"trials":2157,"activeCount":63},[],{"trials":2159,"activeCount":63},[],{"trials":2161,"activeCount":63},[],{"trials":2163,"activeCount":63},[],{"intervention":2150,"totalTrials":12,"cells":2165},{"EARLY_PHASE1":2166,"PHASE1":2168,"PHASE2":2174,"PHASE3":2176,"PHASE4":2178,"NA":2180},{"trials":2167,"activeCount":63},[],{"trials":2169,"activeCount":63},[2170],{"nctId":2143,"briefTitle":2144,"status":453,"phases":2171,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":821,"conditions":2172,"interventions":2173},[52],[18],[2136,2150,2151,2152,2153,2154,2155],{"trials":2175,"activeCount":63},[],{"trials":2177,"activeCount":63},[],{"trials":2179,"activeCount":63},[],{"trials":2181,"activeCount":63},[],{"intervention":2151,"totalTrials":12,"cells":2183},{"EARLY_PHASE1":2184,"PHASE1":2186,"PHASE2":2192,"PHASE3":2194,"PHASE4":2196,"NA":2198},{"trials":2185,"activeCount":63},[],{"trials":2187,"activeCount":63},[2188],{"nctId":2143,"briefTitle":2144,"status":453,"phases":2189,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":821,"conditions":2190,"interventions":2191},[52],[18],[2136,2150,2151,2152,2153,2154,2155],{"trials":2193,"activeCount":63},[],{"trials":2195,"activeCount":63},[],{"trials":2197,"activeCount":63},[],{"trials":2199,"activeCount":63},[],{"intervention":2152,"totalTrials":12,"cells":2201},{"EARLY_PHASE1":2202,"PHASE1":2204,"PHASE2":2210,"PHASE3":2212,"PHASE4":2214,"NA":2216},{"trials":2203,"activeCount":63},[],{"trials":2205,"activeCount":63},[2206],{"nctId":2143,"briefTitle":2144,"status":453,"phases":2207,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":821,"conditions":2208,"interventions":2209},[52],[18],[2136,2150,2151,2152,2153,2154,2155],{"trials":2211,"activeCount":63},[],{"trials":2213,"activeCount":63},[],{"trials":2215,"activeCount":63},[],{"trials":2217,"activeCount":63},[],{"intervention":2153,"totalTrials":12,"cells":2219},{"EARLY_PHASE1":2220,"PHASE1":2222,"PHASE2":2228,"PHASE3":2230,"PHASE4":2232,"NA":2234},{"trials":2221,"activeCount":63},[],{"trials":2223,"activeCount":63},[2224],{"nctId":2143,"briefTitle":2144,"status":453,"phases":2225,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":821,"conditions":2226,"interventions":2227},[52],[18],[2136,2150,2151,2152,2153,2154,2155],{"trials":2229,"activeCount":63},[],{"trials":2231,"activeCount":63},[],{"trials":2233,"activeCount":63},[],{"trials":2235,"activeCount":63},[],{"intervention":2154,"totalTrials":12,"cells":2237},{"EARLY_PHASE1":2238,"PHASE1":2240,"PHASE2":2246,"PHASE3":2248,"PHASE4":2250,"NA":2252},{"trials":2239,"activeCount":63},[],{"trials":2241,"activeCount":63},[2242],{"nctId":2143,"briefTitle":2144,"status":453,"phases":2243,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":821,"conditions":2244,"interventions":2245},[52],[18],[2136,2150,2151,2152,2153,2154,2155],{"trials":2247,"activeCount":63},[],{"trials":2249,"activeCount":63},[],{"trials":2251,"activeCount":63},[],{"trials":2253,"activeCount":63},[],{"intervention":2155,"totalTrials":12,"cells":2255},{"EARLY_PHASE1":2256,"PHASE1":2258,"PHASE2":2264,"PHASE3":2266,"PHASE4":2268,"NA":2270},{"trials":2257,"activeCount":63},[],{"trials":2259,"activeCount":63},[2260],{"nctId":2143,"briefTitle":2144,"status":453,"phases":2261,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":821,"conditions":2262,"interventions":2263},[52],[18],[2136,2150,2151,2152,2153,2154,2155],{"trials":2265,"activeCount":63},[],{"trials":2267,"activeCount":63},[],{"trials":2269,"activeCount":63},[],{"trials":2271,"activeCount":63},[],{"intervention":1276,"totalTrials":12,"cells":2273},{"EARLY_PHASE1":2274,"PHASE1":2276,"PHASE2":2282,"PHASE3":2284,"PHASE4":2286,"NA":2288},{"trials":2275,"activeCount":63},[],{"trials":2277,"activeCount":63},[2278],{"nctId":1267,"briefTitle":1268,"status":69,"phases":2279,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":1272,"conditions":2280,"interventions":2281},[52],[1274],[1276,1250],{"trials":2283,"activeCount":63},[],{"trials":2285,"activeCount":63},[],{"trials":2287,"activeCount":63},[],{"trials":2289,"activeCount":63},[],{"intervention":776,"totalTrials":12,"cells":2291},{"EARLY_PHASE1":2292,"PHASE1":2294,"PHASE2":2300,"PHASE3":2302,"PHASE4":2304,"NA":2306},{"trials":2293,"activeCount":63},[],{"trials":2295,"activeCount":63},[2296],{"nctId":769,"briefTitle":770,"status":69,"phases":2297,"primaryCompletion":772,"completion":772,"start":773,"enrollment":9,"conditions":2298,"interventions":2299},[52],[15],[718,776],{"trials":2301,"activeCount":63},[],{"trials":2303,"activeCount":63},[],{"trials":2305,"activeCount":63},[],{"trials":2307,"activeCount":63},[],{"intervention":2309,"totalTrials":12,"cells":2310},"AC-082",{"EARLY_PHASE1":2311,"PHASE1":2313,"PHASE2":2323,"PHASE3":2325,"PHASE4":2327,"NA":2329},{"trials":2312,"activeCount":63},[],{"trials":2314,"activeCount":63},[2315],{"nctId":2316,"briefTitle":2317,"status":69,"phases":2318,"primaryCompletion":2319,"completion":2319,"start":90,"enrollment":2320,"conditions":2321,"interventions":2322},"NCT02702648","First-in-man Study of Single and Multiple Ascending Doses of a New Drug for Neurological Disorders",[52],"2017-03-06",128,[15],[2309],{"trials":2324,"activeCount":63},[],{"trials":2326,"activeCount":63},[],{"trials":2328,"activeCount":63},[],{"trials":2330,"activeCount":63},[],{"intervention":2332,"totalTrials":12,"cells":2333},"ACT-451840 10 mg",{"EARLY_PHASE1":2334,"PHASE1":2336,"PHASE2":2349,"PHASE3":2351,"PHASE4":2353,"NA":2355},{"trials":2335,"activeCount":63},[],{"trials":2337,"activeCount":63},[2338],{"nctId":2339,"briefTitle":2340,"status":69,"phases":2341,"primaryCompletion":1777,"completion":1777,"start":651,"enrollment":757,"conditions":2342,"interventions":2343},"NCT02186002","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)",[52],[18],[2332,2344,2345,2346,2347,2348],"ACT-451840 50 mg","ACT-451840 200 mg","ACT-451840 500 mg","ACT-451840 1000 mg","ACT-451840",{"trials":2350,"activeCount":63},[],{"trials":2352,"activeCount":63},[],{"trials":2354,"activeCount":63},[],{"trials":2356,"activeCount":63},[],{"intervention":2344,"totalTrials":12,"cells":2358},{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2367,"PHASE3":2369,"PHASE4":2371,"NA":2373},{"trials":2360,"activeCount":63},[],{"trials":2362,"activeCount":63},[2363],{"nctId":2339,"briefTitle":2340,"status":69,"phases":2364,"primaryCompletion":1777,"completion":1777,"start":651,"enrollment":757,"conditions":2365,"interventions":2366},[52],[18],[2332,2344,2345,2346,2347,2348],{"trials":2368,"activeCount":63},[],{"trials":2370,"activeCount":63},[],{"trials":2372,"activeCount":63},[],{"trials":2374,"activeCount":63},[],{"intervention":2345,"totalTrials":12,"cells":2376},{"EARLY_PHASE1":2377,"PHASE1":2379,"PHASE2":2385,"PHASE3":2387,"PHASE4":2389,"NA":2391},{"trials":2378,"activeCount":63},[],{"trials":2380,"activeCount":63},[2381],{"nctId":2339,"briefTitle":2340,"status":69,"phases":2382,"primaryCompletion":1777,"completion":1777,"start":651,"enrollment":757,"conditions":2383,"interventions":2384},[52],[18],[2332,2344,2345,2346,2347,2348],{"trials":2386,"activeCount":63},[],{"trials":2388,"activeCount":63},[],{"trials":2390,"activeCount":63},[],{"trials":2392,"activeCount":63},[],{"intervention":2346,"totalTrials":12,"cells":2394},{"EARLY_PHASE1":2395,"PHASE1":2397,"PHASE2":2403,"PHASE3":2405,"PHASE4":2407,"NA":2409},{"trials":2396,"activeCount":63},[],{"trials":2398,"activeCount":63},[2399],{"nctId":2339,"briefTitle":2340,"status":69,"phases":2400,"primaryCompletion":1777,"completion":1777,"start":651,"enrollment":757,"conditions":2401,"interventions":2402},[52],[18],[2332,2344,2345,2346,2347,2348],{"trials":2404,"activeCount":63},[],{"trials":2406,"activeCount":63},[],{"trials":2408,"activeCount":63},[],{"trials":2410,"activeCount":63},[],{"intervention":2347,"totalTrials":12,"cells":2412},{"EARLY_PHASE1":2413,"PHASE1":2415,"PHASE2":2421,"PHASE3":2423,"PHASE4":2425,"NA":2427},{"trials":2414,"activeCount":63},[],{"trials":2416,"activeCount":63},[2417],{"nctId":2339,"briefTitle":2340,"status":69,"phases":2418,"primaryCompletion":1777,"completion":1777,"start":651,"enrollment":757,"conditions":2419,"interventions":2420},[52],[18],[2332,2344,2345,2346,2347,2348],{"trials":2422,"activeCount":63},[],{"trials":2424,"activeCount":63},[],{"trials":2426,"activeCount":63},[],{"trials":2428,"activeCount":63},[],{"intervention":2348,"totalTrials":12,"cells":2430},{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2439,"PHASE3":2441,"PHASE4":2443,"NA":2445},{"trials":2432,"activeCount":63},[],{"trials":2434,"activeCount":63},[2435],{"nctId":2339,"briefTitle":2340,"status":69,"phases":2436,"primaryCompletion":1777,"completion":1777,"start":651,"enrollment":757,"conditions":2437,"interventions":2438},[52],[18],[2332,2344,2345,2346,2347,2348],{"trials":2440,"activeCount":63},[],{"trials":2442,"activeCount":63},[],{"trials":2444,"activeCount":63},[],{"trials":2446,"activeCount":63},[],{"intervention":178,"totalTrials":12,"cells":2448},{"EARLY_PHASE1":2449,"PHASE1":2451,"PHASE2":2457,"PHASE3":2459,"PHASE4":2461,"NA":2463},{"trials":2450,"activeCount":63},[],{"trials":2452,"activeCount":63},[2453],{"nctId":168,"briefTitle":169,"status":69,"phases":2454,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":2455,"interventions":2456},[52],[18],[177,178,40],{"trials":2458,"activeCount":63},[],{"trials":2460,"activeCount":63},[],{"trials":2462,"activeCount":63},[],{"trials":2464,"activeCount":63},[],{"intervention":1490,"totalTrials":12,"cells":2466},{"EARLY_PHASE1":2467,"PHASE1":2469,"PHASE2":2475,"PHASE3":2477,"PHASE4":2479,"NA":2481},{"trials":2468,"activeCount":63},[],{"trials":2470,"activeCount":63},[2471],{"nctId":1483,"briefTitle":1484,"status":69,"phases":2472,"primaryCompletion":1486,"completion":1486,"start":1487,"enrollment":1472,"conditions":2473,"interventions":2474},[52],[15],[1490,1460,1491,1492,1492],{"trials":2476,"activeCount":63},[],{"trials":2478,"activeCount":63},[],{"trials":2480,"activeCount":63},[],{"trials":2482,"activeCount":63},[],{"intervention":1491,"totalTrials":12,"cells":2484},{"EARLY_PHASE1":2485,"PHASE1":2487,"PHASE2":2493,"PHASE3":2495,"PHASE4":2497,"NA":2499},{"trials":2486,"activeCount":63},[],{"trials":2488,"activeCount":63},[2489],{"nctId":1483,"briefTitle":1484,"status":69,"phases":2490,"primaryCompletion":1486,"completion":1486,"start":1487,"enrollment":1472,"conditions":2491,"interventions":2492},[52],[15],[1490,1460,1491,1492,1492],{"trials":2494,"activeCount":63},[],{"trials":2496,"activeCount":63},[],{"trials":2498,"activeCount":63},[],{"trials":2500,"activeCount":63},[],{"intervention":1492,"totalTrials":12,"cells":2502},{"EARLY_PHASE1":2503,"PHASE1":2505,"PHASE2":2511,"PHASE3":2513,"PHASE4":2515,"NA":2517},{"trials":2504,"activeCount":63},[],{"trials":2506,"activeCount":63},[2507],{"nctId":1483,"briefTitle":1484,"status":69,"phases":2508,"primaryCompletion":1486,"completion":1486,"start":1487,"enrollment":1472,"conditions":2509,"interventions":2510},[52],[15],[1490,1460,1491,1492,1492],{"trials":2512,"activeCount":63},[],{"trials":2514,"activeCount":63},[],{"trials":2516,"activeCount":63},[],{"trials":2518,"activeCount":63},[],{"intervention":94,"totalTrials":12,"cells":2520},{"EARLY_PHASE1":2521,"PHASE1":2523,"PHASE2":2529,"PHASE3":2531,"PHASE4":2533,"NA":2535},{"trials":2522,"activeCount":63},[],{"trials":2524,"activeCount":63},[2525],{"nctId":87,"briefTitle":88,"status":69,"phases":2526,"primaryCompletion":90,"completion":90,"start":91,"enrollment":9,"conditions":2527,"interventions":2528},[52],[27],[45,94],{"trials":2530,"activeCount":63},[],{"trials":2532,"activeCount":63},[],{"trials":2534,"activeCount":63},[],{"trials":2536,"activeCount":63},[],{"intervention":2538,"totalTrials":12,"cells":2539},"ACT541468",{"EARLY_PHASE1":2540,"PHASE1":2542,"PHASE2":2554,"PHASE3":2556,"PHASE4":2558,"NA":2560},{"trials":2541,"activeCount":63},[],{"trials":2543,"activeCount":63},[2544],{"nctId":2545,"briefTitle":2546,"status":69,"phases":2547,"primaryCompletion":2548,"completion":2548,"start":2549,"enrollment":152,"conditions":2550,"interventions":2551},"NCT03907215","A Clinical Study to Examine the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects",[52],"2019-06-26","2019-04-09",[18],[2538,2552,2553],"ACT541468 placebo","Citalopram",{"trials":2555,"activeCount":63},[],{"trials":2557,"activeCount":63},[],{"trials":2559,"activeCount":63},[],{"trials":2561,"activeCount":63},[],{"intervention":2552,"totalTrials":12,"cells":2563},{"EARLY_PHASE1":2564,"PHASE1":2566,"PHASE2":2572,"PHASE3":2574,"PHASE4":2576,"NA":2578},{"trials":2565,"activeCount":63},[],{"trials":2567,"activeCount":63},[2568],{"nctId":2545,"briefTitle":2546,"status":69,"phases":2569,"primaryCompletion":2548,"completion":2548,"start":2549,"enrollment":152,"conditions":2570,"interventions":2571},[52],[18],[2538,2552,2553],{"trials":2573,"activeCount":63},[],{"trials":2575,"activeCount":63},[],{"trials":2577,"activeCount":63},[],{"trials":2579,"activeCount":63},[],{"intervention":2553,"totalTrials":12,"cells":2581},{"EARLY_PHASE1":2582,"PHASE1":2584,"PHASE2":2590,"PHASE3":2592,"PHASE4":2594,"NA":2596},{"trials":2583,"activeCount":63},[],{"trials":2585,"activeCount":63},[2586],{"nctId":2545,"briefTitle":2546,"status":69,"phases":2587,"primaryCompletion":2548,"completion":2548,"start":2549,"enrollment":152,"conditions":2588,"interventions":2589},[52],[18],[2538,2552,2553],{"trials":2591,"activeCount":63},[],{"trials":2593,"activeCount":63},[],{"trials":2595,"activeCount":63},[],{"trials":2597,"activeCount":63},[],{"intervention":365,"totalTrials":12,"cells":2599},{"EARLY_PHASE1":2600,"PHASE1":2602,"PHASE2":2608,"PHASE3":2610,"PHASE4":2612,"NA":2614},{"trials":2601,"activeCount":63},[],{"trials":2603,"activeCount":63},[2604],{"nctId":358,"briefTitle":359,"status":69,"phases":2605,"primaryCompletion":361,"completion":361,"start":362,"enrollment":9,"conditions":2606,"interventions":2607},[52],[15],[351,365],{"trials":2609,"activeCount":63},[],{"trials":2611,"activeCount":63},[],{"trials":2613,"activeCount":63},[],{"trials":2615,"activeCount":63},[],{"intervention":797,"totalTrials":12,"cells":2617},{"EARLY_PHASE1":2618,"PHASE1":2620,"PHASE2":2626,"PHASE3":2628,"PHASE4":2630,"NA":2632},{"trials":2619,"activeCount":63},[],{"trials":2621,"activeCount":63},[2622],{"nctId":788,"briefTitle":789,"status":69,"phases":2623,"primaryCompletion":791,"completion":791,"start":792,"enrollment":793,"conditions":2624,"interventions":2625},[52],[795],[718,797,798],{"trials":2627,"activeCount":63},[],{"trials":2629,"activeCount":63},[],{"trials":2631,"activeCount":63},[],{"trials":2633,"activeCount":63},[],{"intervention":1450,"totalTrials":12,"cells":2635},{"EARLY_PHASE1":2636,"PHASE1":2638,"PHASE2":2644,"PHASE3":2646,"PHASE4":2648,"NA":2650},{"trials":2637,"activeCount":63},[],{"trials":2639,"activeCount":63},[2640],{"nctId":1443,"briefTitle":1444,"status":69,"phases":2641,"primaryCompletion":1446,"completion":1446,"start":1447,"enrollment":783,"conditions":2642,"interventions":2643},[52],[18],[1419,1450],{"trials":2645,"activeCount":63},[],{"trials":2647,"activeCount":63},[],{"trials":2649,"activeCount":63},[],{"trials":2651,"activeCount":63},[],{"intervention":187,"totalTrials":12,"cells":2653},{"EARLY_PHASE1":2654,"PHASE1":2656,"PHASE2":2662,"PHASE3":2664,"PHASE4":2666,"NA":2668},{"trials":2655,"activeCount":63},[],{"trials":2657,"activeCount":63},[2658],{"nctId":180,"briefTitle":181,"status":69,"phases":2659,"primaryCompletion":183,"completion":183,"start":184,"enrollment":152,"conditions":2660,"interventions":2661},[52],[18],[40,187,188],{"trials":2663,"activeCount":63},[],{"trials":2665,"activeCount":63},[],{"trials":2667,"activeCount":63},[],{"trials":2669,"activeCount":63},[],{"intervention":188,"totalTrials":12,"cells":2671},{"EARLY_PHASE1":2672,"PHASE1":2674,"PHASE2":2680,"PHASE3":2682,"PHASE4":2684,"NA":2686},{"trials":2673,"activeCount":63},[],{"trials":2675,"activeCount":63},[2676],{"nctId":180,"briefTitle":181,"status":69,"phases":2677,"primaryCompletion":183,"completion":183,"start":184,"enrollment":152,"conditions":2678,"interventions":2679},[52],[18],[40,187,188],{"trials":2681,"activeCount":63},[],{"trials":2683,"activeCount":63},[],{"trials":2685,"activeCount":63},[],{"trials":2687,"activeCount":63},[],{"intervention":2689,"totalTrials":12,"cells":2690},"AC-084",{"EARLY_PHASE1":2691,"PHASE1":2693,"PHASE2":2703,"PHASE3":2705,"PHASE4":2707,"NA":2709},{"trials":2692,"activeCount":63},[],{"trials":2694,"activeCount":63},[2695],{"nctId":2696,"briefTitle":2697,"status":453,"phases":2698,"primaryCompletion":2699,"completion":2699,"start":2700,"enrollment":821,"conditions":2701,"interventions":2702},"NCT02905253","A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects",[52],"2017-12-10","2016-09-12",[15],[2689],{"trials":2704,"activeCount":63},[],{"trials":2706,"activeCount":63},[],{"trials":2708,"activeCount":63},[],{"trials":2710,"activeCount":63},[],{"intervention":2712,"totalTrials":12,"cells":2713},"Treatment period A",{"EARLY_PHASE1":2714,"PHASE1":2716,"PHASE2":2727,"PHASE3":2729,"PHASE4":2731,"NA":2733},{"trials":2715,"activeCount":63},[],{"trials":2717,"activeCount":63},[2718],{"nctId":2719,"briefTitle":2720,"status":69,"phases":2721,"primaryCompletion":2722,"completion":2722,"start":2723,"enrollment":163,"conditions":2724,"interventions":2725},"NCT05123820","Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470",[52],"2021-11-24","2021-11-13",[1274,18],[2712,2726],"Treatment period B",{"trials":2728,"activeCount":63},[],{"trials":2730,"activeCount":63},[],{"trials":2732,"activeCount":63},[],{"trials":2734,"activeCount":63},[],{"intervention":2726,"totalTrials":12,"cells":2736},{"EARLY_PHASE1":2737,"PHASE1":2739,"PHASE2":2745,"PHASE3":2747,"PHASE4":2749,"NA":2751},{"trials":2738,"activeCount":63},[],{"trials":2740,"activeCount":63},[2741],{"nctId":2719,"briefTitle":2720,"status":69,"phases":2742,"primaryCompletion":2722,"completion":2722,"start":2723,"enrollment":163,"conditions":2743,"interventions":2744},[52],[1274,18],[2712,2726],{"trials":2746,"activeCount":63},[],{"trials":2748,"activeCount":63},[],{"trials":2750,"activeCount":63},[],{"trials":2752,"activeCount":63},[],{"intervention":2754,"totalTrials":12,"cells":2755},"ACT-451840:",{"EARLY_PHASE1":2756,"PHASE1":2758,"PHASE2":2770,"PHASE3":2772,"PHASE4":2774,"NA":2776},{"trials":2757,"activeCount":63},[],{"trials":2759,"activeCount":63},[2760],{"nctId":2761,"briefTitle":2762,"status":69,"phases":2763,"primaryCompletion":2764,"completion":2764,"start":2765,"enrollment":22,"conditions":2766,"interventions":2767},"NCT02223871","Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects",[52],"2014-07","2014-06",[15],[2754,2768,2769],"Artemether 20 mg and lumefantrine 120mg combination tablet:","Primaquine:",{"trials":2771,"activeCount":63},[],{"trials":2773,"activeCount":63},[],{"trials":2775,"activeCount":63},[],{"trials":2777,"activeCount":63},[],{"intervention":2768,"totalTrials":12,"cells":2779},{"EARLY_PHASE1":2780,"PHASE1":2782,"PHASE2":2788,"PHASE3":2790,"PHASE4":2792,"NA":2794},{"trials":2781,"activeCount":63},[],{"trials":2783,"activeCount":63},[2784],{"nctId":2761,"briefTitle":2762,"status":69,"phases":2785,"primaryCompletion":2764,"completion":2764,"start":2765,"enrollment":22,"conditions":2786,"interventions":2787},[52],[15],[2754,2768,2769],{"trials":2789,"activeCount":63},[],{"trials":2791,"activeCount":63},[],{"trials":2793,"activeCount":63},[],{"trials":2795,"activeCount":63},[],{"intervention":2769,"totalTrials":12,"cells":2797},{"EARLY_PHASE1":2798,"PHASE1":2800,"PHASE2":2806,"PHASE3":2808,"PHASE4":2810,"NA":2812},{"trials":2799,"activeCount":63},[],{"trials":2801,"activeCount":63},[2802],{"nctId":2761,"briefTitle":2762,"status":69,"phases":2803,"primaryCompletion":2764,"completion":2764,"start":2765,"enrollment":22,"conditions":2804,"interventions":2805},[52],[15],[2754,2768,2769],{"trials":2807,"activeCount":63},[],{"trials":2809,"activeCount":63},[],{"trials":2811,"activeCount":63},[],{"trials":2813,"activeCount":63},[],{"intervention":2815,"totalTrials":12,"cells":2816},"ACT-462206 5 mg",{"EARLY_PHASE1":2817,"PHASE1":2819,"PHASE2":2838,"PHASE3":2840,"PHASE4":2842,"NA":2844},{"trials":2818,"activeCount":63},[],{"trials":2820,"activeCount":63},[2821],{"nctId":2822,"briefTitle":2823,"status":69,"phases":2824,"primaryCompletion":1196,"completion":1196,"start":1471,"enrollment":821,"conditions":2825,"interventions":2830},"NCT01954589","Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206",[52],[2826,2827,2828,2829],"Safety","Tolerability","Pharmacodynamics","Pharmacokinetics",[2815,2831,2832,2833,2834,2835,2836,2837],"ACT-462206 25 mg","ACT-462206 100mg","ACT-462206 200mg","ACT-462206 400mg","ACT-462206 1000 mg","ACT-462206 1500mg","Almorexant 400mg",{"trials":2839,"activeCount":63},[],{"trials":2841,"activeCount":63},[],{"trials":2843,"activeCount":63},[],{"trials":2845,"activeCount":63},[],{"intervention":2831,"totalTrials":12,"cells":2847},{"EARLY_PHASE1":2848,"PHASE1":2850,"PHASE2":2856,"PHASE3":2858,"PHASE4":2860,"NA":2862},{"trials":2849,"activeCount":63},[],{"trials":2851,"activeCount":63},[2852],{"nctId":2822,"briefTitle":2823,"status":69,"phases":2853,"primaryCompletion":1196,"completion":1196,"start":1471,"enrollment":821,"conditions":2854,"interventions":2855},[52],[2826,2827,2828,2829],[2815,2831,2832,2833,2834,2835,2836,2837],{"trials":2857,"activeCount":63},[],{"trials":2859,"activeCount":63},[],{"trials":2861,"activeCount":63},[],{"trials":2863,"activeCount":63},[],{"intervention":2832,"totalTrials":12,"cells":2865},{"EARLY_PHASE1":2866,"PHASE1":2868,"PHASE2":2874,"PHASE3":2876,"PHASE4":2878,"NA":2880},{"trials":2867,"activeCount":63},[],{"trials":2869,"activeCount":63},[2870],{"nctId":2822,"briefTitle":2823,"status":69,"phases":2871,"primaryCompletion":1196,"completion":1196,"start":1471,"enrollment":821,"conditions":2872,"interventions":2873},[52],[2826,2827,2828,2829],[2815,2831,2832,2833,2834,2835,2836,2837],{"trials":2875,"activeCount":63},[],{"trials":2877,"activeCount":63},[],{"trials":2879,"activeCount":63},[],{"trials":2881,"activeCount":63},[],{"intervention":2833,"totalTrials":12,"cells":2883},{"EARLY_PHASE1":2884,"PHASE1":2886,"PHASE2":2892,"PHASE3":2894,"PHASE4":2896,"NA":2898},{"trials":2885,"activeCount":63},[],{"trials":2887,"activeCount":63},[2888],{"nctId":2822,"briefTitle":2823,"status":69,"phases":2889,"primaryCompletion":1196,"completion":1196,"start":1471,"enrollment":821,"conditions":2890,"interventions":2891},[52],[2826,2827,2828,2829],[2815,2831,2832,2833,2834,2835,2836,2837],{"trials":2893,"activeCount":63},[],{"trials":2895,"activeCount":63},[],{"trials":2897,"activeCount":63},[],{"trials":2899,"activeCount":63},[],{"intervention":2834,"totalTrials":12,"cells":2901},{"EARLY_PHASE1":2902,"PHASE1":2904,"PHASE2":2910,"PHASE3":2912,"PHASE4":2914,"NA":2916},{"trials":2903,"activeCount":63},[],{"trials":2905,"activeCount":63},[2906],{"nctId":2822,"briefTitle":2823,"status":69,"phases":2907,"primaryCompletion":1196,"completion":1196,"start":1471,"enrollment":821,"conditions":2908,"interventions":2909},[52],[2826,2827,2828,2829],[2815,2831,2832,2833,2834,2835,2836,2837],{"trials":2911,"activeCount":63},[],{"trials":2913,"activeCount":63},[],{"trials":2915,"activeCount":63},[],{"trials":2917,"activeCount":63},[],{"intervention":2835,"totalTrials":12,"cells":2919},{"EARLY_PHASE1":2920,"PHASE1":2922,"PHASE2":2928,"PHASE3":2930,"PHASE4":2932,"NA":2934},{"trials":2921,"activeCount":63},[],{"trials":2923,"activeCount":63},[2924],{"nctId":2822,"briefTitle":2823,"status":69,"phases":2925,"primaryCompletion":1196,"completion":1196,"start":1471,"enrollment":821,"conditions":2926,"interventions":2927},[52],[2826,2827,2828,2829],[2815,2831,2832,2833,2834,2835,2836,2837],{"trials":2929,"activeCount":63},[],{"trials":2931,"activeCount":63},[],{"trials":2933,"activeCount":63},[],{"trials":2935,"activeCount":63},[],{"intervention":2836,"totalTrials":12,"cells":2937},{"EARLY_PHASE1":2938,"PHASE1":2940,"PHASE2":2946,"PHASE3":2948,"PHASE4":2950,"NA":2952},{"trials":2939,"activeCount":63},[],{"trials":2941,"activeCount":63},[2942],{"nctId":2822,"briefTitle":2823,"status":69,"phases":2943,"primaryCompletion":1196,"completion":1196,"start":1471,"enrollment":821,"conditions":2944,"interventions":2945},[52],[2826,2827,2828,2829],[2815,2831,2832,2833,2834,2835,2836,2837],{"trials":2947,"activeCount":63},[],{"trials":2949,"activeCount":63},[],{"trials":2951,"activeCount":63},[],{"trials":2953,"activeCount":63},[],{"intervention":2837,"totalTrials":12,"cells":2955},{"EARLY_PHASE1":2956,"PHASE1":2958,"PHASE2":2964,"PHASE3":2966,"PHASE4":2968,"NA":2970},{"trials":2957,"activeCount":63},[],{"trials":2959,"activeCount":63},[2960],{"nctId":2822,"briefTitle":2823,"status":69,"phases":2961,"primaryCompletion":1196,"completion":1196,"start":1471,"enrollment":821,"conditions":2962,"interventions":2963},[52],[2826,2827,2828,2829],[2815,2831,2832,2833,2834,2835,2836,2837],{"trials":2965,"activeCount":63},[],{"trials":2967,"activeCount":63},[],{"trials":2969,"activeCount":63},[],{"trials":2971,"activeCount":63},[],{"intervention":112,"totalTrials":12,"cells":2973},{"EARLY_PHASE1":2974,"PHASE1":2976,"PHASE2":2982,"PHASE3":2984,"PHASE4":2986,"NA":2988},{"trials":2975,"activeCount":63},[],{"trials":2977,"activeCount":63},[2978],{"nctId":105,"briefTitle":106,"status":69,"phases":2979,"primaryCompletion":108,"completion":108,"start":109,"enrollment":9,"conditions":2980,"interventions":2981},[52],[15],[45,112],{"trials":2983,"activeCount":63},[],{"trials":2985,"activeCount":63},[],{"trials":2987,"activeCount":63},[],{"trials":2989,"activeCount":63},[],{"intervention":1294,"totalTrials":12,"cells":2991},{"EARLY_PHASE1":2992,"PHASE1":2994,"PHASE2":3000,"PHASE3":3002,"PHASE4":3004,"NA":3006},{"trials":2993,"activeCount":63},[],{"trials":2995,"activeCount":63},[2996],{"nctId":1286,"briefTitle":1287,"status":69,"phases":2997,"primaryCompletion":1289,"completion":1290,"start":1291,"enrollment":163,"conditions":2998,"interventions":2999},[52],[15],[1294,1250],{"trials":3001,"activeCount":63},[],{"trials":3003,"activeCount":63},[],{"trials":3005,"activeCount":63},[],{"trials":3007,"activeCount":63},[],{"intervention":1344,"totalTrials":12,"cells":3009},{"EARLY_PHASE1":3010,"PHASE1":3012,"PHASE2":3018,"PHASE3":3020,"PHASE4":3022,"NA":3024},{"trials":3011,"activeCount":63},[],{"trials":3013,"activeCount":63},[3014],{"nctId":1335,"briefTitle":1336,"status":69,"phases":3015,"primaryCompletion":830,"completion":1338,"start":1339,"enrollment":1340,"conditions":3016,"interventions":3017},[52],[15],[1343,177,1344],{"trials":3019,"activeCount":63},[],{"trials":3021,"activeCount":63},[],{"trials":3023,"activeCount":63},[],{"trials":3025,"activeCount":63},[],{"intervention":814,"totalTrials":12,"cells":3027},{"EARLY_PHASE1":3028,"PHASE1":3030,"PHASE2":3036,"PHASE3":3038,"PHASE4":3040,"NA":3042},{"trials":3029,"activeCount":63},[],{"trials":3031,"activeCount":63},[3032],{"nctId":808,"briefTitle":809,"status":69,"phases":3033,"primaryCompletion":811,"completion":811,"start":91,"enrollment":757,"conditions":3034,"interventions":3035},[52],[15],[718,718,814],{"trials":3037,"activeCount":63},[],{"trials":3039,"activeCount":63},[],{"trials":3041,"activeCount":63},[],{"trials":3043,"activeCount":63},[],{"intervention":3045,"totalTrials":12,"cells":3046},"ACT-1014-6470 40 mg",{"EARLY_PHASE1":3047,"PHASE1":3049,"PHASE2":3059,"PHASE3":3061,"PHASE4":3063,"NA":3065},{"trials":3048,"activeCount":63},[],{"trials":3050,"activeCount":63},[3051],{"nctId":3052,"briefTitle":3053,"status":69,"phases":3054,"primaryCompletion":3055,"completion":3055,"start":3056,"enrollment":783,"conditions":3057,"interventions":3058},"NCT04899219","A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects",[52],"2021-11-12","2021-06-16",[18],[3045],{"trials":3060,"activeCount":63},[],{"trials":3062,"activeCount":63},[],{"trials":3064,"activeCount":63},[],{"trials":3066,"activeCount":63},[],{"intervention":824,"totalTrials":12,"cells":3068},{"EARLY_PHASE1":3069,"PHASE1":3071,"PHASE2":3077,"PHASE3":3079,"PHASE4":3081,"NA":3083},{"trials":3070,"activeCount":63},[],{"trials":3072,"activeCount":63},[3073],{"nctId":816,"briefTitle":817,"status":69,"phases":3074,"primaryCompletion":819,"completion":819,"start":820,"enrollment":821,"conditions":3075,"interventions":3076},[52],[18],[718,824],{"trials":3078,"activeCount":63},[],{"trials":3080,"activeCount":63},[],{"trials":3082,"activeCount":63},[],{"trials":3084,"activeCount":63},[],{"intervention":513,"totalTrials":12,"cells":3086},{"EARLY_PHASE1":3087,"PHASE1":3089,"PHASE2":3095,"PHASE3":3097,"PHASE4":3099,"NA":3101},{"trials":3088,"activeCount":63},[],{"trials":3090,"activeCount":63},[3091],{"nctId":504,"briefTitle":505,"status":69,"phases":3092,"primaryCompletion":507,"completion":508,"start":509,"enrollment":510,"conditions":3093,"interventions":3094},[52],[15],[497,513],{"trials":3096,"activeCount":63},[],{"trials":3098,"activeCount":63},[],{"trials":3100,"activeCount":63},[],{"trials":3102,"activeCount":63},[],{"intervention":3104,"totalTrials":12,"cells":3105},"ACT-777991",{"EARLY_PHASE1":3106,"PHASE1":3108,"PHASE2":3121,"PHASE3":3123,"PHASE4":3125,"NA":3127},{"trials":3107,"activeCount":63},[],{"trials":3109,"activeCount":63},[3110],{"nctId":3111,"briefTitle":3112,"status":69,"phases":3113,"primaryCompletion":3114,"completion":3115,"start":3116,"enrollment":3117,"conditions":3118,"interventions":3119},"NCT04798209","A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects",[52],"2022-01-26","2022-05-21","2021-01-29",70,[18],[3104,3104,3120,3120],"14C-ACT-777991 microtracer",{"trials":3122,"activeCount":63},[],{"trials":3124,"activeCount":63},[],{"trials":3126,"activeCount":63},[],{"trials":3128,"activeCount":63},[],{"intervention":3120,"totalTrials":12,"cells":3130},{"EARLY_PHASE1":3131,"PHASE1":3133,"PHASE2":3139,"PHASE3":3141,"PHASE4":3143,"NA":3145},{"trials":3132,"activeCount":63},[],{"trials":3134,"activeCount":63},[3135],{"nctId":3111,"briefTitle":3112,"status":69,"phases":3136,"primaryCompletion":3114,"completion":3115,"start":3116,"enrollment":3117,"conditions":3137,"interventions":3138},[52],[18],[3104,3104,3120,3120],{"trials":3140,"activeCount":63},[],{"trials":3142,"activeCount":63},[],{"trials":3144,"activeCount":63},[],{"trials":3146,"activeCount":63},[],{"intervention":1353,"totalTrials":12,"cells":3148},{"EARLY_PHASE1":3149,"PHASE1":3151,"PHASE2":3157,"PHASE3":3159,"PHASE4":3161,"NA":3163},{"trials":3150,"activeCount":63},[],{"trials":3152,"activeCount":63},[3153],{"nctId":1346,"briefTitle":1347,"status":69,"phases":3154,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":163,"conditions":3155,"interventions":3156},[52],[18],[177,1353],{"trials":3158,"activeCount":63},[],{"trials":3160,"activeCount":63},[],{"trials":3162,"activeCount":63},[],{"trials":3164,"activeCount":63},[],{"intervention":1583,"totalTrials":12,"cells":3166},{"EARLY_PHASE1":3167,"PHASE1":3169,"PHASE2":3175,"PHASE3":3177,"PHASE4":3179,"NA":3181},{"trials":3168,"activeCount":63},[],{"trials":3170,"activeCount":63},[3171],{"nctId":1576,"briefTitle":1577,"status":69,"phases":3172,"primaryCompletion":1579,"completion":1579,"start":1580,"enrollment":1549,"conditions":3173,"interventions":3174},[52],[18],[1561,1561,1583,1584],{"trials":3176,"activeCount":63},[],{"trials":3178,"activeCount":63},[],{"trials":3180,"activeCount":63},[],{"trials":3182,"activeCount":63},[],{"intervention":1584,"totalTrials":12,"cells":3184},{"EARLY_PHASE1":3185,"PHASE1":3187,"PHASE2":3193,"PHASE3":3195,"PHASE4":3197,"NA":3199},{"trials":3186,"activeCount":63},[],{"trials":3188,"activeCount":63},[3189],{"nctId":1576,"briefTitle":1577,"status":69,"phases":3190,"primaryCompletion":1579,"completion":1579,"start":1580,"enrollment":1549,"conditions":3191,"interventions":3192},[52],[18],[1561,1561,1583,1584],{"trials":3194,"activeCount":63},[],{"trials":3196,"activeCount":63},[],{"trials":3198,"activeCount":63},[],{"trials":3200,"activeCount":63},[],{"intervention":3202,"totalTrials":12,"cells":3203},"14C-radiolabeled ACT-132577",{"EARLY_PHASE1":3204,"PHASE1":3206,"PHASE2":3216,"PHASE3":3218,"PHASE4":3220,"NA":3222},{"trials":3205,"activeCount":63},[],{"trials":3207,"activeCount":63},[3208],{"nctId":3209,"briefTitle":3210,"status":69,"phases":3211,"primaryCompletion":3212,"completion":3212,"start":3213,"enrollment":1251,"conditions":3214,"interventions":3215},"NCT03100591","A Study to Evaluate ACT-132577 in Healthy Male Subjects",[52],"2017-04-18","2017-03-28",[15],[3202],{"trials":3217,"activeCount":63},[],{"trials":3219,"activeCount":63},[],{"trials":3221,"activeCount":63},[],{"trials":3223,"activeCount":63},[],{"intervention":3225,"totalTrials":12,"cells":3226},"Aprocitentan 25mg",{"EARLY_PHASE1":3227,"PHASE1":3229,"PHASE2":3239,"PHASE3":3241,"PHASE4":3243,"NA":3245},{"trials":3228,"activeCount":63},[],{"trials":3230,"activeCount":63},[3231],{"nctId":3232,"briefTitle":3233,"status":69,"phases":3234,"primaryCompletion":3235,"completion":3235,"start":3236,"enrollment":163,"conditions":3237,"interventions":3238},"NCT03586570","A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects",[52],"2018-09-10","2018-07-17",[15],[3225],{"trials":3240,"activeCount":63},[],{"trials":3242,"activeCount":63},[],{"trials":3244,"activeCount":63},[],{"trials":3246,"activeCount":63},[]]